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A B S T R A C T
Background
The presence and progression of hepatic (liver) fibrosis into cirrhosis is a prognostic variable having impact on survival in people with
alcoholic liver disease. Liver biopsy, although an invasive method, is the recommended ’reference standard’ for diagnosis and staging of
hepatic fibrosis in people with liver diseases. Transient elastography is a non-invasive method for assessing and staging hepatic fibrosis.
Objectives
To determine the diagnostic accuracy of transient elastography for diagnosis and staging hepatic fibrosis in people with alcoholic liver
disease when compared with liver biopsy. To identify the optimal cut-off values for differentiating the five stages of hepatic fibrosis.
Search methods
The Cochrane Hepato-Biliary Group Controlled and Diagnostic Test Accuracy Studies Registers, The Cochrane Library, MEDLINE
(OvidSP), EMBASE (OvidSP), and the Science Citation Index Expanded (last search August 2014).
Selection criteria
Diagnostic cohort and diagnostic case-control study designs that assessed hepatic fibrosis in participants with alcoholic liver disease with
transient elastography and liver biopsy, irrespective of language or publication status. The study participants could be of any sex and
ethnic origin, above 16 years old, hospitalised or managed as outpatients. We excluded participants with viral hepatitis, autoimmunity,
metabolic diseases, and toxins.
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Data collection and analysis
We followed the guidelines in the draft Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy.
Main results
Five retrospective and nine prospective cohort studies with 834 participants provided data for the review analyses. Authors of seven of
those studies sent us individual participant data. The risk of bias in the included studies was high in all but three studies. We could
identify no serious concerns regarding the applicability of the studies in answering the main study question of our review, namely to
use transient elastography to diagnose hepatic fibrosis. We could not identify the optimal cut-off values for the fibrosis stages. The
definition of the diagnosis of alcoholic liver disease was not provided in one study and was not clearly defined in two studies, but it was
clear in the remaining 11 studies. The study authors used different liver stiffness cut-off values of transient elastography for the hepatic
fibrosis stages.
There was only one study (103 participants) with data on hepatic fibrosis stage F1 or worse, with a cut-off of 5.9 kPa, and reporting
sensitivity of 0.83 (95% confidence interval (CI) 0.74 to 0.90) and specificity of 0.88 (95% CI 0.47 to 1.00). The summary sensitivity
and specificity of transient elastography for F2 or worse (seven studies with 338 participants and with cut-offs around 7.5 kPa (range
7.00 to 7.8 kPa)) were 0.94 and 0.89 with LR+ 8.2 and LR- 0.07, which suggests that transient elastography could be useful to rule
out the presence of significant hepatic fibrosis, thus avoiding liver biopsy.
Due to the wide range of cut-off values (from 8.0 to 17.0 kPa) found in the 10 studies with 760 participants with hepatic fibrosis F3
or worse, we fitted a hierarchical summary receiver operating characteristic (HSROC) model and estimated a summary ROC (SROC)
curve. The sensitivity of the 10 studies varied from 72% to 100% and the specificity from 59% to 89%. We performed an additional
analysis by including the studies with a cut-off value of around and equal to 9.5 kPa (range 8.0 to 11.0 kPa). The summary sensitivity
and specificity of transient elastography (eight studies with 564 participants) were 0.92 and 0.70 with LR+ 3.1 and LR- 0.11, which
suggests that transient elastography could also be useful to rule out the presence of severe hepatic fibrosis (F3 or worse), avoiding liver
biopsy. We carried out a sensitivity analysis by considering only the studies with a cut-off value equal to 9.5 kPa and the result did not
differ.
We performed anHSROC analysis and reported an SROC curve for hepatic fibrosis stage F4 (cirrhosis). TheHSROC analysis suggested
that when the cut-off value changes, there is a wide variation in specificity and a more limited variation in sensitivity. We performed an
additional analysis with the studies with the most commonly used cut-off value of 12.5 kPa. The summary sensitivity and specificity
of transient elastography (seven studies with 330 participants) were 0.95 and 0.71 with LR+ 3.3 and LR- 0.07, which again suggests
that transient elastography could be useful to rule out the presence of cirrhosis, avoiding liver biopsy.
Authors’ conclusions
We identified a small number of studies with a few participants and were unable to include several studies, which raises the risk of
outcome reporting bias. With these caveats in mind, transient elastography may be used as a diagnostic method to rule out liver cirrhosis
(F4) in people with alcoholic liver disease when the pre-test probability is about 51% (range 15% to 79%). Transient elastography may
also help in ruling out severe fibrosis (F3 or worse). Liver biopsy investigation remains an option if the certainty to rule in or rule out
the stage of hepatic fibrosis or cirrhosis remains insufficient after a clinical follow-up or any other non-invasive test considered useful
by the clinician.
The proposed cut-off values for the different stages of hepatic fibrosis may be used in clinical practice, but caution is needed, as those
values reported in this review are only the most common cut-off values used by the study authors. The best cut-off values for hepatic
fibrosis in people with alcoholic liver disease could not be established yet.
In order to diagnose correctly the stage of hepatic fibrosis in people with alcoholic liver disease using transient elastography assessment,
the studies should consider a single aetiology. Hepatic fibrosis should be diagnosed with both transient elastography and liver biopsy
and in this sequence, and transient elastography cut-off values should be pre-specified and validated. The time interval between the
two investigations should not exceed three months, which is the interval mainly valid for people without cirrhosis, and assessment of
results should be properly blinded. Only studies with low risk of bias, fulfilling the Standards for Reporting of Diagnostic Accuracy
may answer the review question.
P L A I N L A N G U A G E S U M M A R Y
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Transient elastography for measurement of liver fibrosis and cirrhosis in people with alcoholic liver disease
Background
Liver fibrosis is a change in the microscopic structure of the liver because of liver inflammation. After many years of excessive alcohol
consumption, liver fibrosis progresses to cirrhosis. Abstaining from alcohol may stop the fibrosis from further progression into significant
or severe fibrosis and cirrhosis. The latter lead to complications of underlying diseases, including cancer.
Measurement of the amount of fibrosis is called staging. There are five stages (F0: no scarring (no fibrosis); F1: minimal scarring; F2:
scarring has occurred and extends outside the liver area (significant fibrosis); F3: fibrosis spreading and forming bridges with other
fibrotic liver areas (severe fibrosis); F4: cirrhosis or advanced scarring). Cut-off values may distinguish between the different stages of
fibrosis, but in people with alcoholic liver disease, the best cut-off values have not been determined yet.
Rationale
Liver biopsy is where a sample of tissue is taken from the liver using a small needle. It is the standard method of detecting and measuring
fibrosis.
Transient elastography measures stiffening of the liver caused by progressive scarring, but it has not been validated in people with
alcoholic liver disease.
Aims
To find out how well transient elastography may determine the presence or absence of fibrosis and if it can stage fibrosis in people with
alcoholic liver disease when compared with liver biopsy.
Methods
Using Cochrane methods and searching the literature (August 2014), the review authors obtained results from 14 studies (834 partic-
ipants), out of which only seven included people with only alcoholic liver disease. Participants underwent both transient elastography
(the index test) and liver biopsy (the standard test).
Findings and conclusions
The number of studies and participants was small and the participants had different severity of liver fibrosis. Only four studies were
judged good quality.
Transient elastography fibrosis stage F2 or worse (significant fibrosis)
There were seven studies with 338 participants: 81% of people had significant fibrosis. Out of 1000 people, 810 will have significant
fibrosis. Of these 810 people, 49 people would be missed even though they had significant fibrosis. A clinical follow-up could provide
physicians with knowledge for the next diagnostic step. The remaining 190 people would not have significant fibrosis; 21 people would
have unnecessary worries about their liver fibrosis stage.
Transient elastography fibrosis stage F3 or worse (severe fibrosis)
There were eight studies with 564 participants: 61% of people had severe fibrosis. Out of 1000 people, 610 would have severe fibrosis.
Of these 610 people, 49 people would be missed even though they had severe fibrosis. A clinical follow-up could provide physicians with
knowledge for the next diagnostic step. The remaining 390 people would not have severe fibrosis; 117 people would have unnecessary
worries about their liver fibrosis stage.
Transient elastography fibrosis stage F4 (cirrhosis)
There were seven studies with 330 participants: 51% of people had cirrhosis. Out of 1000 people, 510 will have cirrhosis. Of these
510 people, 26 people would be missed even though they had cirrhosis. A clinical follow-up could provide physicians with knowledge
for the next diagnostic step. The remaining 490 people would not have cirrhosis; 143 people would have unnecessary worries about
their liver fibrosis stage.
Transient elastography may be used as a diagnostic tool to rule out liver cirrhosis and may also help in ruling out severe fibrosis in people
with alcoholic liver disease. Liver biopsy investigation still remains an option if the certainty to rule in or rule out the stage of hepatic
fibrosis or cirrhosis remains insufficient after a clinical follow-up or any other non-invasive test considered useful by the clinician.
The best cut-off values for differentiating between the five liver fibrosis stages could still not be established.
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Future studies should include only people with alcoholic liver disease. Hepatic fibrosis should be diagnosed with transient elastography
followed by liver biopsy and the transient elastography cut-off values of liver stiffness for the different stages of liver fibrosis should be
decided before the test occurs. The time interval between the two tests should not exceed three months, an interval that is mainly valid
for people without cirrhosis. Assessors of results should be unaware of the treatment given.
B A C K G R O U N D
Transient elastography is a widely used non-invasive method for
assessing and staging hepatic fibrosis (scarring of the liver tissue).
Transient elastography measures stiffening of the liver, which is
caused by progressive scarring. Transient elastography assessment
of hepatic (liver) fibrosis has already been validated inmany people
with chronic liver diseases of various aetiologies (Sandrin 2003;
Nahon 2008). It is important to define the cut-off values that
could differentiate hepatic fibrosis stages. In fact, cut-off levels for
specific stages of hepatic fibrosis vary according to the aetiology
of the chronic liver disease. In people with alcoholic liver disease,
such cut-off values have not been established and validated yet
(Rockey 2008).
Excessive alcohol consumption may lead to alcohol-related liver
disease. Every year, alcohol use kills 2.5 million people, including
320,000 young people between 15 and 29 years of age. Alcohol is
the third leading risk factor for poor health globally, and harmful
use of alcohol was responsible for almost 4% of all deaths in the
world, according to the estimates for 2004 (WHO 2010). Alco-
holism is a disease that damages the brain, liver, heart, and other
organs. Heavy alcohol consumption can lead to brain shrinkage,
dementia, alcoholism, cancer, and death. Negative effects of al-
cohol include liver damage and multiple liver diseases, including
liver cirrhosis and cancer (Bruha 2012).
The presence and progression of hepatic fibrosis into cirrhosis is
a main prognostic variable having impact on survival in people
with alcoholic liver disease. Transient elastography may indicate
the amount of hepatic fibrosis in people with alcoholic liver disease
(de Lédinghen 2010). A number of clinical studies have compared
liver stiffness measured by transient elastography with presence
and histological staging of hepatic fibrosis by liver biopsy, reaching
a conclusion that transient elastography is a reliable method for
assessment of hepatic fibrosis (Foucher 2006; Gómez-Domínguez
2006; Ivashkin 2011a; Tsochatzis 2011). In addition, studies have
found a correlation between the level of liver stiffness and the
degree of hepatic fibrosis in people with alcoholic liver disease
(Nguyen-Khac 2008; Nahon 2009; Mueller 2010). The preva-
lence of hepatic fibrosis in heavy drinkers is not well known. In
a series of 1407 people with alcoholic liver disease diagnosed on
liver biopsy, 809 (57.5%) people had developed hepatic fibrosis
(Naveau 1997). Accurate detection of hepatic fibrosis stage is im-
portant for prognosis of hepatic fibrosis and choice of treatment
in people with alcohol-related liver injury (O’Shea 2010).
Target condition being diagnosed
Hepatic fibrosis in people with alcoholic liver disease
All people with alcoholic liver disease are at risk of developing hep-
atic fibrosis. This risk is considered higher in people who are binge
drinkers, people with increased serum alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) levels, or in people
with severe alcohol hepatitis on liver biopsy (Bouchier 1992).
Hepatic fibrosis may develop as a result of weekly alcohol con-
sumption of seven to 13 alcoholic beverages for women (one bev-
erage = 12 g alcohol) and 14 to 27 alcoholic beverages for men in
the course of five or more years (Savolainen 1993; Becker 1996).
The risk ratio of progression of fibrosis to cirrhosis increases signif-
icantly with a daily consumption of 20 g to 40 g ethanol in women
andmore than 80 g ethanol inmen (Sherlock 1997;O’Shea2010).
The liver is themain site of alcoholmetabolism acting through two
hepatic enzymes, alcohol dehydrogenase and cytochrome P-450
(CYP) 2E1. Increased alcohol intake disrupts the metabolic liver
function, and, as a result, alcoholic liver disease develops (Stewart
2001). Histologically, alcoholic liver disease occurs in three forms:
fatty liver or steatosis, alcoholic hepatitis, and chronic hepatitis
with hepatic fibrosis and cirrhosis (O’Shea 2010). Morphological
features that predict progression to hepatic fibrosis and cirrhosis
include severe steatosis, giant mitochondria, and the presence of
mixed macrovesicular-microvesicular steatosis (Teli 1995).
Early staging of hepatic fibrosis in people with alcoholic liver dis-
eases could motivate patients and physicians in finding an opti-
mal strategy for achieving abstinence. A single staging system for
evaluating hepatic fibrosis in alcoholic liver disease does not exist.
METAVIR is the most widely used scoring system for interpre-
tation of liver biopsy results based on the stage of fibrosis where
F0 indicates no fibrosis, F1 indicates portal fibrous expansion, F2
indicates thin fibrous septa emanating from portal triads, F3 in-
dicates fibrous septa bridging portal triads and central veins, and
F4 indicates cirrhosis (Table 1). Hepatic fibrosis could be consid-
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ered clinically significant if defined as F2 or worse than F2, us-
ing METAVIR score (Franciscus 2007). Hepatic fibrosis could be
considered clinically severe if defined as F3 or worse than F3, using
METAVIR score (F3 and F4). In Table 1, we have also included
other widely used systems for classification of hepatic fibrosis in
people with alcoholic liver disease (Knodell 1981; Desmet 1994;
Ishak 1995; Brunt 1999; Kleiner 2005), as liver pathologists have
reached no universal consensus on the standardisation of scoring
systems.
Index test(s)
Transient elastography is designed to measure liver stiffness, using
FibroScan® equipment (Echosens, Paris, France; Echosens 2009).
A probe, consisting of an ultrasound transducer located at the
end of a vibrating piston, is put on the skin surface overlying the
liver while the person is in the supine position. After pressing the
button on the probe, a pulse wave is transmitted across the liver
parenchyma. After a short interval, a second ultrasound wave is
transmitted. The difference between the velocities of the twowaves
in the liver parenchyma is calculated using the Doppler technique
(Sandrin 2003; Nahon 2008). As it is known from physical prin-
ciples, the velocity of the pulse wave increases with the stiffness
of the liver parenchyma, corresponding to increasing severity of
fibrosis.
Liver stiffness is expressed as themedian value of 10 validmeasure-
ments in kiloPascals (kPa). The findings of ’normal’ liver stiffness
values for apparently healthy women and men differ in different
studies, lying between 3.3 kPa and 7.0 kPa, using the 5th and
95th percentiles (Roulot 2008; Kim 2012). While age is does not
affect liver stiffness, men compared to women have slightly higher
liver stiffness values (Roulot 2008). A pre-defined cut-off of 8.00
kPa is predictive of severe hepatic fibrosis in alcoholic liver disease,
of F3 or worse by the METAVIR scoring system (Mueller 2010).
The transient elastography method is non-invasive, simple, highly
reproducible, and allows examination of at least 100 times larger
volume of liver tissue compared to a liver sample obtained through
liver biopsy (de Lédinghen 2008). This is why the sampling er-
ror of transient elastography investigation is considered less than
with liver biopsy (Ingiliz 2009). Transient elastography increases
its diagnostic accuracy when applied in combination with serum
markers (Castera 2010). The diagnostic accuracy of transient elas-
tography was compared with alternative tests such as acoustic ra-
diation forced impulse (ARFI) imaging and enhanced liver fibrosis
(ELF) test, concluding that transient elastography can be used for
diagnosis of hepatic fibrosis alone or in combination with any of
them (Crespo 2012). Janssens et al. have shown that transient elas-
tography is more accurate than currently available serum markers
for people with chronic hepatitis C (Janssens 2010). However, the
diagnostic accuracy of transient elastography in people with alco-
holic liver disease is not established yet.
Alternative test(s)
Different methods to perform elasticity measurements have been
developed since 1990. They are aimed at quantifying the elastic-
ity or viscoelasticity of the liver tissue. There are two common
elements in every elasticity imaging method: a force or stress is
applied on the liver tissue and the obtained mechanical response
is measured.
Siemens Ltd. (i.e., ACUSON S2000) has developed a medical
technology that can detect hepatic fibrosis, and hence, it enables
the quantification of the hepatic fibrosis in its different stages. The
technology is also called liver elastography, performed using ARFI
imaging (Iyo 2009). ARFI imaging is faster than conventional
methods as ARFI uses higher frequencies that are comparable to
those used in colour Doppler imaging. The images have greater
contrast and the boundary of the focal lesions are better defined
compared with the conventional ultrasonography imagining tech-
niques (Iyo 2009).
Ultrasonography measures the progression or regression of hep-
atic fibrosis in alcoholic liver disease (Caballeria 1998). It allows
investigation of the hepatic tissue through generation of ultra-
sonic waves. Different ultrasonography impedance indices based
on Echo-colour Doppler variables of the liver blood flow have
been proposed for indirect estimation of the stage of hepatic fibro-
sis (Ersoz 1999; Hizli 2010; Ivashkin 2011a). We undertook this
systematic review to assess the diagnostic accuracy of ultrasonog-
raphy for staging hepatic fibrosis and detecting cirrhosis in people
with alcoholic liver disease (Pavlov 2014a).
Supersonic shear imaging (SSI) is a technique that uses tissue elas-
ticity to detect hepatic fibrosis and steatosis. It is based on velocity
estimation of a shear wave, generated by a radiation force (Bercoff
2004).
Magnetic resonance elastography (MRE) combines magnetic res-
onance imaging (MRI) with sound waves to create a visual map
(elastogram) showing the stiffness of the liver tissue. It is used pri-
marily to detect hardening of the liver caused by different types of
liver diseases, including those of alcoholic aetiology (Jin 2007).
Other alternative non-invasive tests (apart from venepuncture) to
transient elastography are laboratory tests such as AST (aspartate
aminotransferase) to ALT (alanine aminotransferase) ratio, pro-
thrombin index, hyaluronic acid, ELF, etc. (Crespo 2012; Liu
2012). All of these tests are used as surrogate markers for staging
of hepatic fibrosis (Gluud 2007). In addition, different combina-
tions of biochemical tests such as FibroTest® and Fibrometre®
are used for diagnosis and staging of hepatic fibrosis in people with
alcoholic liver disease (Morra 2007; Poynard 2007; Poynard 2008;
Angulo 2009a). We are also undertaking a systematic review to
determine the diagnostic accuracy of transient elastography plus
FibroTest® versus FibroTest® alone for diagnosis of hepatic fi-
brosis in adults with chronic hepatitis C (Pavlov 2014b).
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Clinical pathway
Figure 1 presents the clinical pathway in diagnosis of alcoholic
liver disease.
Figure 1. Clinical pathway in the diagnosis of alcoholic liver disease.
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Rationale
Liver biopsy has so far been considered the standard method for
detection of hepatic fibrosis and its staging, using different semi-
quantitative morphological scores on liver tissue samples with a
size of no more than 1 to 2 cm3 (Table 1). One advantage of liver
biopsy is that it may give diagnostic information for concurrent
liver diseases (Poulsen 1979; Ismail 2011). However, there are a
number of disadvantages with liver biopsy. It is invasive, and itmay
have potential risks to the person, such as punctures of abdominal
organs and haemorrhage. Liver biopsy can be painful, time-con-
suming, and stressful for the person and depends on the physi-
cian’s experience and skills (Grant 1999; O’Shea 2010; Ivashkin
2011b). The risk of haemorrhage and death after a percutaneous
liver biopsy is especially higher in people with a platelet count of
60,000 per mm3 or less, and also in people with an international
normalisation ratio greater than 1.3 (Seeff 2010). Transjugular
liver biopsy seemed a safer alternative for people with low numbers
of platelets or clotting abnormalities. The small size of the tissue
samples, either obtained transcutaneously or via the transjugular
route, may also lead to sampling errors.
Consensus on using transient elastography as a non-invasive
method for diagnosis of hepatic fibrosis has not been established
(Rockey 2008; Sagir 2008; Colli 2010; Yashima 2011; Yoshioka
2013). As for interventions, clinicians should request solid evi-
dence for diagnostic tests (Colli 2014). It has been shown that con-
founding factors such as inflammation, cholestasis, and increased
hepatic vein congestion (e.g., chronic heart failure), influence the
precision of transient elastography irrespective of the aetiology of
the underlying liver disease (Rockey 2008; Colli 2010). Increased
body mass index, sex, and age are not considered confounding
factors, but they may affect the number of reliable results (i.e.,
success rate).
Published meta-analyses demonstrated that cause of liver disease
is the most important factor leading to heterogeneity of tran-
sient elastography results, thus indicating that the different chronic
liver diseases should be analysed separately (Friedrich-Rust 2008;
Poynard 2008; Stebbing 2010; Tsochatzis 2011). However, these
meta-analyses obtained results for all causes of liver disease to-
gether, which may become a limitation for determining the di-
agnostic accuracy of the method of transient elastography when
used to diagnose hepatic fibrosis in people with alcoholic liver dis-
ease. Furthermore, these meta-analyses did not examine in detail
the possible confounding influences of factors such as the degree
of hepatic steatosis or the level of liver inflammation activity in
people with alcoholic liver disease (Savolainen 1993). This review
aimed to complete present research and to study further the diag-
nostic accuracy of transient elastography in detecting the presence
or absence of hepatic fibrosis in people with alcoholic liver dis-
ease, and to establish the optimal cut-off values for differentiating
between the hepatic fibrosis stages, following The Cochrane Col-
laboration methodology (SRDTA Handbook). In addition, this
review will help researchers working on designing interventions
for people with alcoholic liver disease by knowing the grade and
progression of fibrosis and cirrhosis.
O B J E C T I V E S
To determine the diagnostic accuracy of transient elastography
for diagnosis and staging hepatic fibrosis in people with alcoholic
liver disease when compared with liver biopsy. In addition, to
identify the optimal cut-off values for differentiating the five stages
of hepatic fibrosis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We sought to include diagnostic cohort studies and diagnostic
case-control studies that had assessed hepatic fibrosis in partici-
pants with alcoholic liver disease through transient elastography
and liver biopsy, irrespective of language or publication status, or
whether data were collected prospectively or retrospectively. We
considered studies for inclusion also if they had included partici-
pants with different aetiologies of liver disease.
Participants
The studies had to include participants of any sex and ethnic ori-
gin, above 16 years old, and diagnosed with alcoholic liver dis-
ease. The participants could have been hospitalised or managed as
outpatients. The diagnosis of alcoholic liver disease in the study
participants had to be established based on registered history of
excessive intake of alcohol of sufficient duration and quantity to-
gether with clinical evidence of liver disease expressed with phys-
ical signs at examination and followed by laboratory evidence of
liver disease. To ascertain the diagnosis of alcoholic liver disease
and study the presence or absence of hepatic fibrosis or cirrhosis,
the studies had to perform both transient elastography and liver
biopsy (Bouchier 1992).
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For this review, we did not consider for inclusion data on partici-
pants diagnosed with alcoholic liver disease and having a concomi-
tant liver disease such as non-alcoholic fatty liver disease, chronic
hepatitis C virus infection, chronic hepatitis B virus infection, au-
toimmune liver disease, or human immunodeficiency virus (HIV)
infection. We extracted data on study participants with alcoholic
liver disease alone whenever such data were available in the study
report or whenever we could obtain the data required for the re-
view through personal communication with study authors. In the
latter case, we disregarded some of the data presented in the pub-
lication and used the data provided by the study authors through
personal communication.
Index tests
Transient elastography, a non-invasive testmeasuring liver stiffness
in kiloPascals (kPa).
Following the recommended technical parameters for transient
elastography and to ensure the validity of the transient elastogra-
phy result for every participant in the single studies, participants
should have undergone at least 10 validated stiffness measure-
ments at the same measurement point. The measurements should
have had an interquartile range of 30% or less, and the ratio of
the number of successful measurements to the total number of
acquisitions should have been 60% or less (Echosens 2009). We
only considered data from people who provided the full set of the
described data.
Transient elastography is not recommended for use in pregnant
women, people with pacemakers, and people with ascites. Factors
that may influence the success of transient elastography investi-
gation are experience of the operator and body mass index of the
person. Liver stiffness measurement can produce biased results de-
pending on the grade of necro-inflammation and grade of steatosis
(Myers 2010).
Target conditions
The presence of hepatic fibrosis in people with alcoholic liver dis-
ease. Based on the METAVIR histopathological score for inter-
preting liver biopsy, there are five stages of hepatic fibrosis (Table
1).
• F0: no fibrosis.
• F1: mild fibrosis.
• F2: significant fibrosis.
• F3: severe fibrosis.
• F4: cirrhosis.
We dichotomised the hepatic fibrosis estimated by the METAVIR
score as follows:
• people with METAVIR score of F1 or worse were
considered ’diseased’ and people with METAVIR score of F0 are
considered ’non-diseased’;
• people with METAVIR score of F2 or worse were
considered ’diseased’ and people with METAVIR score of F0
plus F1 are considered ’non-diseased’;
• people with METAVIR score of F3 or worse were
considered ’diseased’ and people with METAVIR score of F0
plus F1 plus F2 are considered ’non-diseased’;
• people with METAVIR score of F4 were considered
’diseased’ and people with METAVIR score of F0 plus F1 plus
F2 plus F3 are considered ’non-diseased’.
Reference standards
Liver biopsy is the reference standard that is obtained by percuta-
neous needle techniques, transjugular method, ultrasound-guided
fine-needle, or surgical specimens (Kuntz 2008; Ivashkin 2011b).
Liver biopsy is the only existing reference standard so far for diag-
nosing hepatic fibrosis stages in people with alcoholic liver disease.
Specimens of liver tissue with a mean length of at least 15 mm and
at least seven portal tracts are among the factors that can provide
reliable morphological staging of hepatic fibrosis and grading of
inflammation (Rockey 2009).
If liver biopsy samples were reported with any of the semi-
quantitative scores, that is, METAVIR (Franciscus 2007), Kn-
odell (Franciscus 2007), Ishak (Franciscus 2007), Kleiner (Kleiner
2005), Scheuer (Regev 2002), Brunt (Brunt 1999), or Batts-Lud-
wig (Haque 2010), we used a conversion grid for hepatic fibrosis
staging adapted after Goodman 2007 (Table 1) to unify results on
the grade of hepatic fibrosis on liver biopsy. For grading alcoholic
steatosis, we used the Nonalcoholic Steatohepatitis Clinical Re-
search Network scoring system (Kleiner 2005) (Table 2).
Search methods for identification of studies
We combined electronic searches with reading references of iden-
tified studies of possible interest.
Electronic searches
We searchedTheCochraneHepato-BiliaryGroupControlledTri-
als Register (August 2014), The Cochrane Hepato-Biliary Group
Diagnostic Test Accuracy Studies Register (August 2014), The
Cochrane Library (2014, Issue 7), MEDLINE (OvidSP) (1946 to
August 2014), EMBASE (OvidSP) (1974 to August 2014), and
Science Citation Index Expanded (1900 to August 2014) (Royle
2003; de Vet 2008).
We also screened references of the retrieved studies to identify
other potentially relevant studies for inclusion in our review.
Appendix 1 shows the search strategies for the different databases
with the time spans for the searches. The given search strategies
did not differ from those provided in the published protocol.
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Searching other resources
Abstracts, published in conference proceedings or presented as
posters, were also eligible for inclusion if retrieved with the search
results or if found in the reference lists of the studies of interest to
this review.
Data collection and analysis
We followed the guidelines provided in the Cochrane Handbook
for Diagnostic Test Accuracy Reviews, which is still in preparation
(Reitsma 2005; de Vet 2008).
Selection of studies
Two review authors (CP andDN) independently identified studies
for possible inclusion in the review. By reading titles or abstracts or
both of the identified studies, we excluded references with a study
design not fulfilling the inclusion criteria of our review protocol.
Then, we retrieved the full text of the remaining references. Dur-
ing this second selection, we grouped multiple publications on a
study fulfilling the inclusion criteria together, and then screened
these publications for complimentary data or checked them for
discrepancies of data. If in doubt, CP and DN wrote emails to the
study authors.
The studies that we included assessed transient elastography in
the diagnosis of hepatic fibrosis severity using liver biopsy as the
reference standard.
The maximum time interval between liver biopsy and transient
elastography investigations was not to exceed three months. How-
ever, at the time of extraction of study data for our review, we
decided to also include studies with intervals of more than three
months, and then perform sensitivity analyses in which we in-
cluded studies with up to three months’ interval between the liver
biopsy and transient elastography assessments.
Data extraction and management
Two review authors (CP and DN) extracted data, using a data
extraction sheet. Two other review authors (GC and ET) checked
the extraction of all data. A fifth review author (CG) was an ar-
bitrator in case of disagreements between the review authors who
extracted the information.
We extracted the following data: study origin, year and language of
publication, study design, participants’ epidemiological and labo-
ratory characteristics, definitionof alcoholic liver disease as defined
by the authors of the individual studies considered for inclusion,
technical failures in undertaking liver biopsy and transient elas-
tography, cut-off values of liver stiffness, grade of hepatic fibrosis
estimated by a morphological score, and information related to
the QUADAS-2 items for evaluation of the bias risk of the studies
(Whiting 2011).
In order to provide data for our analyses, the studies had to provide
data that could help us calculate the true positive (TP), false pos-
itive (FP), true negative (TN), and false negative (FN) diagnostic
values of the reference standard, liver biopsy, as well as the index
test, transient elastography, for diagnosing the stages of hepatic
fibrosis, based on semi-quantitative morphological scores and cut-
off points for liver stiffness, and as described by the authors of the
identified studies.
If information on any of the TP, FP, FN, and TN diagnostic test
values or results were missing, we attempted to contact the authors
of the included studies in order to obtain this or other missing
information.
In the cases when authors sent us individual data, we extracted
data on the TP, FP, FN, and TN using the most common cut-off
value for each target condition.
Assessment of methodological quality
Design flaws in test accuracy studies can produce biased results
(Lijmer 1999; Whiting 2004; Rutjes 2006). In addition, evalua-
tion of study results is quite often impossible due to incomplete
reporting (Smidt 2005).
To limit the influence of different biases, three review authors
(CP, GC, and DN) independently assessed the bias risk of the
included diagnostic test accuracy studies, using QUADAS-2 do-
mains (Whiting 2011). A fourth review author (ET) acted as an
arbitrator in case of disagreements between the review authors as-
sessing the bias risk of the studies. To assess correctly the bias risk
of the studies, we attempted to contact study authors for more
information on methodology
The presented items in Appendix 2 are adopted to serve the pur-
poses of our review in addressing the patient spectrum, index test,
target condition, and reference standard, and flow and timing, and
which answers would also reflect the overall quality of the included
studies.
QUADAS-2 is not used to generate a summary ’quality score’
because of the well-known problems associated with such scores
(Jüni 1999; Whiting 2005). If a study is judged as ’low’ on all
domains relating to bias or applicability, then it is appropriate to
have an overall judgement of ’low risk of bias’ or ’low concern
regarding applicability’ for that study. If a study is judged as ’high’
or ’unclear’ on one or more domains, then it may be judged ’at
risk of bias’ or as having ’concerns regarding applicability’.
We used tabular and graphical displays to summarise QUADAS-
2 assessments.
Statistical analysis and data synthesis
We carried out the analyses following Chapter 10 (Analysing and
Presenting Results), as recommended in the Cochrane Handbook
for Systematic Reviews of Diagnostic Test Accuracy (Macaskill 2010).
We used the Review Manager 5 software for analyses and plots
(RevMan 2012).
9Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We built two-by-two tables of the transient elastography perfor-
mance (TP, TN, FP, FN) for each primary study and for all of
the pre-defined target conditions (mild hepatic fibrosis, signifi-
cant hepatic fibrosis, severe hepatic fibrosis, and cirrhosis). We es-
timated sensitivity, specificity, positive and negative likelihood ra-
tios (LR+ and LR-), positive and negative predictive values (PPV
and NPV) with their 95% confidence intervals (CI). First, we
performed a graphical descriptive analysis of the included stud-
ies: we reported forest plots (sensitivity and specificity separately,
with their 95% CIs) and we provided a graphical representation
of the studies in the receiver operating characteristic (ROC) space
(sensitivity against 1 - specificity). Second, where appropriate, we
performed ameta-analysis. When the primary studies reported ac-
curacy estimates of transient elastography using different cut-off
points, we used the hierarchical summary ROCmodel (HSROC)
to pool data (sensitivities and specificities) and to plot a summary
ROC (SROC) curve (Rutter 2001). When considering studies
with a common cut-off, we used the bivariate model and we pro-
vided the estimate of the summary operating point (the point with
mean sensitivity and mean specificity). Finally, when, due to a
low variability of sensitivity or specificity (or both) across studies,
the bivariate model failed to converge, we fitted a bivariate model
without random effects, and we estimated a summary operating
point. In particular, we performed the analyses using bivariate
models with random effects for only specificity (or for only sensi-
tivity) or bivariate models without random effects, as appropriate
(Macaskill 2010).
The pooled estimates obtained from the fitted models were used
to calculate summary estimates of LRs. We assessed the usefulness
of transient elastography to rule in or to rule out hepatic fibrosis
by considering the estimates of likelihood ratios. An LR+ greater
than 10 means that there is a large increase in post-test probability,
starting from pre-test probability. An LR- lower than 0.1 means
that there is a large decrease in post-test probability, starting from
pre-test probability (Schoenfeld 1999).
For primary studies that reported accuracy results for more than
one cut-off point, we reported sensitivities and specificities for all
of the cut-off points, but we used a single cut-off point for each
study inHSROC (or bivariatemodel) analysis.We planned to base
the choice of the cut-off value on the maximum of the Youden’s
index (sensitivity + specificity - 1), but instead, we decided to use
themost commonly reported cut-off value for each stage of hepatic
fibrosis whenever these data were available in the published articles
or retrieved through personal communication.
Finally, whenever possible, we added some relevant co-variates (see
Investigations of heterogeneity) to the bivariate or HSROCmodel
to investigate the effect of the pre-defined sources of heterogeneity.
One review author (GC) did all statistical analyses performedwith
SAS statistical software, release 9.2 (SAS Institute Inc., Cary, NC,
USA).
Investigations of heterogeneity
We attempted to investigate the sources of heterogeneity by evalu-
ating differences of diagnostic accuracy in pre-defined subgroups,
related to:
• liver biopsy as the reference standard:
◦ different grade of inflammation according to the liver
biopsy (below two grades compared to two or greater grades of
activity);
◦ different lengths of liver biopsy sample (less than 15
mm compared to 15 mm or more than 15 mm);
◦ different number of portal tracts included in a liver
biopsy sample (less than seven compared to seven or more than
seven);
◦ different grades of steatosis according to the liver
biopsy (less than 5% compared to 5% or more than 5%);
◦ mild fibrosis compared to significant fibrosis compared
to severe fibrosis or cirrhosis as estimated by the different semi-
quantitative histopathological scoring systems used (see Table 1);
• population group:
◦ different body mass indices (below 25 kg/m2
compared to 25 kg/m2 or more than 25 kg/m2) (WHO);
◦ serum levels of AST activity (normal, i.e., 5 to 35 U/L,
compared to twice the upper limit (Dufour 2000));
• definition of alcoholic liver disease.
We attempted to evaluate the effect of the above-mentioned
sources of heterogeneity on the accuracy estimates by adding co-
variates to the bivariate or HSROC models.
Sensitivity analyses
We attempted to assess the effect of risk of bias of the included
studies on the diagnostic accuracy by performing a sensitivity anal-
ysis, excluding studies with high risk of bias. We classified a study
with high risk of bias if judged as high risk of bias or unclear risk
of bias in at least one of the domains of QUADAS-2 (Appendix
2).
Moreover, to assess the effect of time interval between transient
elastography and liver biopsy, we performed a second sensitivity
analysis by considering only studies with up to three months’ in-
terval.
Due to variation of cut-off values, overlap of cut-off values, and
lack of sufficient data to produce subgroup analyses, we performed
one additional sensitivity analysis in which we removed studies
with cut-off values different to the most common cut-off value of
9.5 kPa for severe fibrosis and cirrhosis (see Data table 5).
Assessment of reporting bias
Using the suggested method by Deeks et al. (Deeks 2005), we
performed a funnel plot to investigate the reporting bias by visual
inspection of the patterns drawn from study data, where lack of
symmetry should denote high risk of reporting bias (Figure 2).
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Figure 2. Funnel plot for reporting bias for liver fibrosis F4 in 14 included studiesEven though the Figure is
not in the form of a funnel plot, it seems that there is no clear indication of reporting bias as the points were
equally distributed along the x- and y-axes. There seems to be two outliers (to the right) (Bardou-Jacquet
2013; Carl 2012): both studies had a small number of participants (eight and four).
R E S U L T S
Results of the search
We identified 3111 references through electronic searches of
the Cochrane Hepato-Biliary Group Controlled Trials Regis-
ter (two references), Cochrane Hepato-Biliary Group Diagnos-
tic Test Accuracy Register (27 references), The Cochrane Library
(38 references), MEDLINE (OvidSP) (485 references), EMBASE
(OvidSP) (1671), and Science Citation Index Expanded (885 ref-
erences). We identified no additional studies by searching other
sources. After exclusion of duplicates, 2198 references remained.
Having performed two selections, we found 2129 hits to be irrel-
evant references. Forty-one references seemed to fulfil the inclu-
sion criteria. However, we had to exclude 13 of these, and thus 28
references remained for further assessment. As data for the two-
by-two tables could not be extracted from seven of these study
publications, 21 references remained, describing 14 studies and
providing data for themeta-analysis. We added one additional ref-
erence towards the final stage of the review because we received
a substantial amount of information from the study author (de
Ledinghen 2013). Thus, 22 references describing 14 studies pro-
vided data for the meta-analysis of our review.
Eight of the 13 excluded studies (referred to above) could have been
included in our review had the number of participants been five or
more than five and had it been possible to build up a two-by-two
table with the available data (Characteristics of excluded studies).
An exception from the latter explanation was the included study
by Carl 2012 with four participants only, as we received individual
participant data from the study author, and in this way, we could
use the provided data in a two-by-two table. In the remaining 13
included studies, the number of participants ranged from eight to
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147. As some of the studies included participants with different
liver diseases, for the purpose of our review, we extracted data only
on participants diagnosed with alcoholic liver disease alone (see
Included studies; Characteristics of included studies).
In total, seven study authors provided individual participant data
of people with alcoholic liver disease (Boursier 2009; Kim 2009;
Anastasiou 2010; Carl 2012; de Ledinghen 2013; Dolman 2013;
Lannerstedt 2013) (for details, see Characteristics of included
studies). However, even after personal communication, we could
not collect all missing information of relevance to our review anal-
yses.
We found no diagnostic case-control studies that met the selection
criteria. No studies are awaiting classification. Figure 3 shows the
reference flow.
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Figure 3. Flow chart.
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Characteristics of included studies
We have summarised the characteristics of the 14 included studies
in the Characteristics of included studies table.
Study design
Nine of the included studies were prospective cohort studies (
Nahon 2008; Lemoine 2008; Nguyen-Khac 2008; Boursier 2009;
Kim 2009; Anastasiou 2010; Janssens 2010; Mueller 2010; de
Ledinghen 2013), and five were retrospective cohort studies (Carl
2012; Fernandez 2012; Bardou-Jacquet 2013; Dolman 2013;
Lannerstedt 2013).
Funding
Five of the studies declared no financial interest and support by the
manufacturer of transient elastography equipment (Nahon 2008;
Lemoine 2008; Nguyen-Khac 2008; Janssens 2010; Dolman
2013), while this information was either missing or unclear in the
remaining nine studies.
Participants
Only seven of the 14 studies included participants with alcoholic
liver disease aetiology (Nahon 2008; Nguyen-Khac 2008; Kim
2009; Janssens 2010; Mueller 2010; Fernandez 2012; Bardou-
Jacquet 2013); the participants in the remaining seven studies had
chronic liver disease with different aetiologies, among which was
alcoholic liver disease. The number of participants with alcoholic
liver disease in the 14 studies was 834, and all participants un-
derwent both the index test (transient elastography) and the ref-
erence standard (liver biopsy) and were included in our analyses.
The definition of the diagnosis of alcoholic liver disease was not
provided in one study (Carl 2012), was not clearly defined in two
studies (Fernandez 2012; Dolman 2013), but the definition was
clear in the remaining 11 studies.
Seven studies reported the body mass index of participants as 25
kg/m2 or greater (Nahon 2008; Nguyen-Khac 2008; Boursier
2009; Janssens 2010; Mueller 2010; de Ledinghen 2013; Dolman
2013), three studies below25 kg/m2 (Kim2009; Anastasiou 2010;
Lannerstedt 2013), and four studies provided no information.
In 12 studies, the serum levels of AST activity was greater than 35
U/L. Bardou-Jacquet 2013 provided AST data for 13 abstinent
and 24 relapsers separately; however, it was not possible to extract
the data separately for the eight participants included in our anal-
yses. There was no information provided in the study by Dolman
2013, but through personal communication with the study au-
thor, we understood that AST had not been routinely available in
their centre at the time of the study.
The maximum time interval of investigation with liver biopsy and
transient elastography was within six months in 11 studies (Nahon
2008; Lemoine 2008; Nguyen-Khac 2008; Boursier 2009; Kim
2009; Anastasiou 2010; Janssens 2010; Mueller 2010; Fernandez
2012; de Ledinghen 2013; Dolman 2013). The time interval in
the study by Lannerstedt 2013 was less than three months in 50%
of the participants and more than three months (range 1.9 to 8.6
years) in the remaining 50%. Bardou-Jacquet 2013 reported a
median time interval of 32.5 weeks in six of the eight participants.
The time internal in the study by Carl 2012 was unclear.
Liver biopsy morphological scoring systems
The morphological scoring systems in the 14 studies used to as-
sess hepatic fibrosis on liver biopsy were as follows: METAVIR
in nine studies (Nguyen-Khac 2008; Boursier 2009; Anastasiou
2010; Janssens 2010; Fernandez 2012; Bardou-Jacquet 2013; de
Ledinghen 2013; Dolman 2013; Lannerstedt 2013), and Ishak
(Carl 2012), Batts-Ludwig (Kim 2009), Chevallier (Lemoine
2008), Kleiner (Mueller 2010), and Brunt and Chevallier (Nahon
2008), in one study each.
Length of liver biopsy specimen
Nine studies provided the length of liver biopsy specimen and it
was more than 10 mm (Nahon 2008; Lemoine 2008; Nguyen-
Khac 2008; Boursier 2009; Kim 2009; Anastasiou 2010; de
Ledinghen 2013; Dolman 2013; Lannerstedt 2013). The remain-
ing five studies provided no information.
Number of portal tracts
Three studies reported the number of portal tracts to be more than
seven (Nguyen-Khac 2008; Dolman 2013; Lannerstedt 2013).
The remaining 11 studies provided no information.
Level of inflammation
Five studies reported the level of inflammation less than two grades
of activity (Nahon 2008; Nguyen-Khac 2008; Anastasiou 2010;
Dolman 2013; Lannerstedt 2013). The remaining nine studies
provided no information.
Grade of steatosis
Seven studies found the grade of steatosis to be more than 5%
(Nahon 2008; Nguyen-Khac 2008; Kim 2009; Janssens 2010; de
Ledinghen 2013; Dolman 2013; Lannerstedt 2013). The remain-
ing seven studies provided no information.
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Study information on the index test - transient elastography
In six of the 14 studies, the authors used pre-defined cut-off values
for staging hepatic fibrosis (Nahon 2008; Janssens 2010; Mueller
2010; Bardou-Jacquet 2013; Dolman 2013; Lannerstedt 2013).
In the remaining eight studies, the authors used cut-off values that
were established during the study.
One study with 103 participants provided data for fibrosis stages
F1 or worse (Nguyen-Khac 2008); eight studies with 342 partici-
pants provided data for fibrosis stages F2 or worse (Nguyen-Khac
2008; Boursier 2009; Kim 2009; Anastasiou 2010; Carl 2012; de
Ledinghen 2013; Dolman 2013; Lannerstedt 2013); 10 studies
with 760 participants provided data for fibrosis stages F3 or worse
(Nahon 2008; Nguyen-Khac 2008; Boursier 2009; Kim 2009;
Janssens 2010; Mueller 2010; Fernandez 2012; de Ledinghen
2013; Dolman 2013; Lannerstedt 2013); and all 14 studies with
834 participants provided data for fibrosis stage F4 (i.e., cirrhosis).
Methodological quality of included studies
Figure 4 and Figure 5 summarise the methodological quality in
the included studies. Only four studies were at low risk of bias in
all domains (Nahon 2008; Janssens 2010; Mueller 2010; Dolman
2013).
Figure 4. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies.
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Figure 5. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
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Participant selection
Thirteen studieswere at low risk of bias in the ’patient selection’ do-
main (Nahon 2008; Lemoine 2008; Nguyen-Khac 2008; Boursier
2009; Kim 2009; Anastasiou 2010; Janssens 2010; Mueller 2010;
Fernandez 2012; Bardou-Jacquet 2013; de Ledinghen 2013;
Dolman 2013; Lannerstedt 2013). One study was at unclear risk
of bias in the ’patient selection’ domain as it was not clear if Carl
et al. had avoided inappropriate exclusions (Carl 2012) (Figure
5). However, we judged that all 14 studies had low concern about
applicability in this domain (Figure 5).
Index test
Five studies were at low risk of bias as they had pre-specified cut-off
values and results were interpreted without the knowledge of the
reference standard result (i.e., blinding) (Nahon 2008; Janssens
2010; Mueller 2010; Dolman 2013; Lannerstedt 2013), seven
studies were at high risk of bias as cut-off values were not pre-spec-
ified (Lemoine 2008; Nguyen-Khac 2008; Boursier 2009; Kim
2009; Anastasiou 2010; Fernandez 2012; de Ledinghen 2013),
and two studies were at unclear risk of bias in the ’index test’
domain (Carl 2012 (no information about blinding or pre-speci-
fied cut-off values); Bardou-Jacquet 2013 (no information about
blinding)) (Figure 5). Besides lack of pre-specified cut-off values
in Fernandez 2012, it was unclear whether the index test results
were interpreted without the knowledge of the reference standard
result. We judged that all 14 studies had low concern about appli-
cability in this domain (Figure 5).
Reference standard
Eleven studies were at low risk of bias (Nahon 2008; Lemoine
2008; Nguyen-Khac 2008; Boursier 2009; Kim 2009; Anastasiou
2010; Janssens 2010; Mueller 2010; de Ledinghen 2013; Dolman
2013; Lannerstedt 2013), and three were at unclear risk of bias in
the ’reference standard’ domain as there was no information about
blinding (Carl 2012; Fernandez 2012; Bardou-Jacquet 2013) (
Figure 5). However, we judged that all 14 studies had low concern
about applicability in this domain (Figure 5).
Flow and timing
Eight studies were at low risk of bias (Lemoine 2008;Nahon 2008;
Nguyen-Khac 2008; Kim 2009; Anastasiou 2010; Janssens 2010;
Mueller 2010; Dolman 2013), four studies were at high risk of
bias (Bardou-Jacquet 2013 (due to inappropriate time interval and
exclusion of participants from the analyses); Boursier 2009 (due to
exclusion of participants from the analyses); de Ledinghen 2013
(due to exclusion of participants from the analyses); Lannerstedt
2013 (due to inappropriate time interval)), and two studies were at
unclear risk of bias in the ’flow and timing’ domain due to unclear
time intervals in the studies (Carl 2012; Fernandez 2012) (Figure
5).
We made our judgements based on the following information.
Bardou-Jacquet 2013 reported that two of the eight participants
had their liver biopsy within four weeks’ interval and the remain-
ing six participants had their liver biopsy performed during the
follow-up period of between 15 and 85 weeks. The study included
participants with excessive alcohol consumption, and at the end
of follow-up all but one participant were relapsers and had ad-
vanced stage of fibrosis on liver biopsy and transient elastography
(i.e., cirrhosis). In the de Ledinghen 2013 study, even though the
flow and timing was within one week, not all participants were
included in the analyses, which made the study of high risk of bias
in this domain.
The time interval between liver biopsy and transient elastography
was not clear in three studies. Carl 2012 reported that participants
underwent liver biopsy and transient elastography between 1May
2008 and 31 July 2011; Fernandez 2012 reported that transient
elastography was performed within six months of liver biopsy in
the 139 consecutive participants with alcoholic liver disease; and
Lannerstedt 2013 reported that the time interval between liver
biopsy and transient elastography was less than three months in
50% of the participants and more than three months (range 1.9 to
8.6 years) in the remaining 50%). As all of the eight participants
(i.e., 50%) with the time interval of more than six months had
cirrhosis, it is unlikely that the stage of fibrosis (i.e., cirrhosis)
would improve.
Liver biopsy seemed to have been performed before transient
elastography in six studies (Nahon 2008; Nguyen-Khac 2008;
Boursier 2009; Anastasiou 2010; Fernandez 2012; Lannerstedt
2013), and after transient elastography in three studies (Lemoine
2008; Janssens 2010; Dolman 2013). In the remaining five stud-
ies, it was unclear which test was performed first.
Findings
Transient elastography for F1 or worse
One study with 103 participants provided data for transient elas-
tography assessing people with hepatic fibrosis stage F1 or worse
(Nguyen-Khac 2008) (Data table 1). The cut-off value for F1 was
5.9 kPa.
Transient elastography for F2 or worse
Eight studieswith 342participants provideddata for transient elas-
tography assessing people with hepatic fibrosis stage F2 or worse
(Nguyen-Khac 2008; Boursier 2009; Kim2009; Anastasiou 2010;
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Carl 2012; de Ledinghen 2013; Dolman 2013; Lannerstedt 2013)
(Data table 2). The sensitivity of the eight studies varied from 75%
to 100% and the specificity from 80% to 100% (Figure 6). The
cut-off values in seven studies were around 7.5 kPa (range 7.00 to
7.8 kPa). As the cut-off value in one study with four participants
was 13.5 kPa (Carl 2012), we decided to conduct a meta-analysis
by including the studies with cut-off values around 7.5 kPa only.
Figure 6. Forest plot: Transient elastography for F2 or worse.
We fitted the bivariate model to the seven studies with 338 partic-
ipants and estimated a summary operating point (a point with the
mean sensitivity and specificity of the transient elastography test).
We obtained the following results: sensitivity 0.94 (95% CI 0.86
to 0.97); specificity 0.89 (95% CI 0.76 to 0.95); positive likeli-
hood ratio (LR+) 8.2 (95% CI 3.6 to 18.5); negative likelihood
ratio (LR-) 0.07 (95% CI 0.03 to 0.17) (Figure 7).
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Figure 7. Summary operating point and 95% confidence region: Transient elastography for F2 or worse with
cut-offs around 7.5 kPa.
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The mean prevalence of F2 or worse in the seven studies was
81%. Using this value as a pre-test probability, we obtained a post-
test probability of 97% when the test was positive and a post-
test probability of 23% when the test was negative (Summary of
findings).
Transient elastography for F3 or worse
Ten studies with 760 participants provided data for transient elas-
tography assessing people with hepatic fibrosis stage F3 or worse
(Nahon 2008; Nguyen-Khac 2008; Boursier 2009; Kim 2009;
Janssens 2010; Mueller 2010; Fernandez 2012; de Ledinghen
2013; Dolman 2013; Lannerstedt 2013) (Data table 3). The sen-
sitivity of the 10 studies varied from 72% to 100% and the speci-
ficity from 59% to 89% (Figure 8). The cut-off values in the 10
studies ranged from 8.0 to 17.0 kPa. We used the HSROC model
and it was possible to estimate a summary receiver-operating char-
acteristic curve (SROC) (Data and analyses; Figure 9).
Figure 8. Forest plot: Transient elastography for F3 or worse.
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Figure 9. Hierarchical summary receiver operating characteristic (ROC) curve: Transient elastography for
F3 or worse. The cut-offs in the nine studies ranged from 8.0 to 17.0 kPa.
The sensitivity analysis on studieswith up to threemonths’ interval
could not provide results, due to a statistical problem (the model
did not converge).
Transient elastography for F3 or worse with cut-off values
around 9.5 KPa
When we considered the eight studies with 564 participants us-
ing cut-off values around 9.5 KPa (range 8 to 11 kPa), it was
possible to estimate a summary operating point (a point with the
mean sensitivity and specificity of the transient elastography test)
(Nguyen-Khac 2008; Boursier 2009; Kim 2009; Mueller 2010;
Fernandez 2012; de Ledinghen 2013; Dolman 2013; Lannerstedt
2013) (Data table 4). The sensitivity of the eight studies varied
from 80% to 100% and the specificity from 50% to 80% (Figure
10). Using a bivariate method (with random effect for only speci-
ficity), we obtained the following results: sensitivity 0.92 (95%
CI 0.89 to 0.96); specificity 0.70 (95% CI 0.61 to 0.79); positive
likelihood ratio (LR+) 3.1 (95% CI 2.1 to 4.1); negative likeli-
hood ratio (LR-) 0.11 (95% CI 0.06 to 0.16) (Figure 11).
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Figure 10. Forest plot: Transient elastography for F3 or worse with cut-offs around 9.5 kPa.
Figure 11. Summary operating point and 95% confidence region: Transient elastography for F3 or worse
with cut-offs around 9.5 kPa.
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The mean prevalence of F3 or worse in these eight studies was
61%. Using this value as a pre-test probability, we obtained a post-
test probability of 83% when the test was positive and a post-
test probability of 15% when the test was negative (Summary of
findings).
Transient elastography for F3 or worse with cut-off values
around 9.5 kPa and time interval within three months -
sensitivity analysis
When we considered only the seven studies with 425 participants
with up to three months’ interval between transient elastography
and liver biopsy, the pooled estimates obtained using a bivariate
method (with random effect for only specificity) were as follows:
sensitivity 0.90 (95% CI 0.86 to 0.95); specificity 0.69 (95% CI
0.46 to 0.92); positive likelihood ratio (LR+) 2.9 (95% CI 0.8
to 5.1); negative likelihood ratio (LR-) 0.14 (95% CI 0.06 to
0.22), showing that the pooled results were not noticeably affected
when we excluded the study with a time interval longer than three
months (Fernandez 2012).
Transient elastography for F3 or worse with a cut-off value
of 9.5 kPa - sensitivity analysis
When we considered the five studies with 221 participants using
a cut-off of 9.5 kPa, it was possible to estimate a summary op-
erating point (a point with the mean sensitivity and specificity
of the transient elastography test). Using a bivariate method, we
obtained the following results: sensitivity 0.92 (95% CI 0.83 to
0.97); specificity 0.68 (95% CI 0.52 to 0.80); positive likelihood
ratio (LR+) 2.9 (95%CI 1.8 to 4.5); negative likelihood ratio (LR-
) 0.11 (95% CI 0.05 to 0.27).
The mean prevalence of F3 or worse in these five studies was
78%. Using this value as a pre-test probability, we obtained a post-
test probability of 91% when the test was positive and a post-
test probability of 28% when the test was negative (Summary of
findings).
Transient elastography for F4
Fourteen studies with 834 participants using nine different cut-
off values ranging from 7.15 to 34.9 kPa provided data for
transient elastography assessing people with hepatic fibrosis for
F4 (Nahon 2008; Nguyen-Khac 2008; Lemoine 2008; Boursier
2009; Kim 2009; Anastasiou 2010; Janssens 2010; Mueller 2010;
Carl 2012; Fernandez 2012; Bardou-Jacquet 2013; de Ledinghen
2013; Dolman 2013; Lannerstedt 2013) (Data table 6). The sen-
sitivity of the 14 studies varied from 75% to 100% and the speci-
ficity from 33% to 94% (Figure 12). We used the HSROCmodel
and it was possible to estimate the SROC curve (Figure 13), which
showed that the variation between the different values of the cut-
off values seemed to affect more specificity than the sensitivity of
the index test.
Figure 12. Forest plot: Transient elastography for F4.
23Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 13. Hierarchical summary receiver operating characteristic (ROC) curve: Transient elastography for
F4.
Transient elastography for F4 and time interval within three
months - sensitivity analysis
When we considered only the 10 studies with 667 participants
with up to three months’ interval between transient elastography
and liver biopsy, the obtained SROC curve (Figure 14) was sim-
ilar to the curve obtained when considering all 14 studies; the
results were not noticeably affected when we excluded the four
studies with time intervals longer than three months (Carl 2012;
Fernandez 2012; Bardou-Jacquet 2013; Lannerstedt 2013).
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Figure 14. Hierarchical summary receiver operating characteristic (ROC) curve: Transient elastography for
F4 (cirrhosis): only studies with time interval between transient elastography and liver biopsy within three
months.
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Transient elastography for F4 with a cut-off value 12.5 kPa -
sensitivity analysis
We performed the analysis with seven studies reporting a cut-
off of 12.5 kPa (the most common cut-off for F4) in which
330 participants were tested (Boursier 2009; Kim 2009; Mueller
2010; Bardou-Jacquet 2013; de Ledinghen 2013; Dolman 2013;
Lannerstedt 2013) (Data table 7). The sensitivity of the seven
studies varied from 90% to 100% and the specificity from 33%
to 94% (Figure 15). Using a bivariate model, we obtained the fol-
lowing results: sensitivity 0.95 (95% CI 0.87 to 0.98); specificity
0.71 (95% CI 0.56 to 0.82); positive likelihood ratio (LR+) 3.3
(95% CI 2.1 to 5.0); negative likelihood ratio (LR-) 0.07 (95%
CI 0.03 to 0.19) (Figure 16).
Figure 15. Forest plot: Transient elastography for F4 (most common cut-off = 12.5 kPa).
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Figure 16. Summary operating point and 95% confidence region: Transient elastography for F4 (cirrhosis)
with the most common cut-off = 12.5 kPa.
The mean prevalence of F4 in these seven studies was 51%. Using
this value as a pre-test probability, we obtained a post-test proba-
bility of 77% when the test was positive and a post-test probability
of 7% when the test was negative (Summary of findings).
Transient elastography for F4 with a cut-off value 12.5 kPa
and time interval within three months - sensitivity analysis
In order to provide an estimate for accuracywith themost common
cut-off of 12.5 kPa and considering only the studies with up to
threemonths’ interval between transient elastography and the liver
biopsy, we performed a separate analysis in which five studies with
306 participants could be included (Boursier 2009; Kim 2009;
Mueller 2010; de Ledinghen 2013; Dolman 2013). The results
changed slightly: sensitivity 0.94 (95%CI0.87 to 0.97); specificity
0.76 (95% CI 0.63 to 0.85); positive likelihood ratio (LR+) 3.8
(95% CI 2.5 to 6.0); negative likelihood ratio (LR-) 0.08 (95%
CI 0.04 to 0.17), showing that the pooled results were not affected
when we excluded the two studies with time interval longer than
three months (Bardou-Jacquet 2013; Lannerstedt 2013).
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Investigation of heterogeneity
Despite the fact that we could collect data for sources of hetero-
geneity, it was not possible to perform formal analyses to explore
the effect as almost all studies had the same covariate values.
Reporting bias
The funnel plot for investigation of reporting bias in the 14 studies
reporting on hepatic fibrosis F4 (cirrhosis) did not seem to raise
concerns as the studies were equally distributed along the x- and
y- axes and the two outliers were studies with a small number
of participants (four participants, Carl 2012; eight participants,
Bardou-Jacquet 2013) (Figure 2). For stages of fibrosis of F1 to
F3, we did not attempt to construct funnel plots, as the number
of studies with data were fewer than 10.
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Summary of findings
What is the diagnostic accuracy of transient elastography examination for the different stages of hepatic fibrosis or cirrhosis at different cut-off values?
Patients/population: people (men and women) diagnosed with alcoholic liver disease on liver biopsy and transient elastography
Prior testing: -
Settings: outpatients and inpatients.
Index test: transient elastography.
Importance: transient elastography is a non-invasive test. The risk of the liver biopsy performance and complications is avoided
Reference standard: liver biopsy.
Studies: cross-sectional studies. No case-control studies were found
Individual patient data: obtained from 7 studies.
Stage of hepatic fibrosis Summary accuracy
(95% CI)







when the test is positive
Post-test
probability when the test
is negative
Quality and comments
Transient elastography fibrosis stage F2 or worse
Cut-off around 7.5 kPa
(range 7.0 to 7.8). Signif-
icant fibrosis
Sensitivity 0.94 (95% CI
0.86 to 0.97)
Specificity 0.89 (95% CI
0.76 to 0.95)
LR+ 8.2 (95% CI 3.6 to
18.5)
LR- 0.07 (95% CI 0.03 to
0.17)
338 participants (7 stud-
ies)
81% (range 29% to 97%) With a prevalence of 81%,
810 out of 1000 people
will have significant fibro-
sis. Of these 810 people,
49 (6% of 810) people
will be missed as having
significant fibrosis. A clin-
ical follow-up can provide
physicians with knowl-
edge for the next diag-
nostic step that should be
taken
The remaining 190 people
will not have significant
Positive test 97%*
Negative test 23%*
The overall quality of the
studies in terms of bias
risk was assessed as
moderate
3 (43%) of the studies
included 20 or <than 20
participants
Study design (mixed aeti-
ologies); risk of selection
bias (not all participants

































































































































fibrosis. 21 people (11%
of 190), i.e., the false
positives, will have un-
necessary worries about
their liver fibrosis stage.
However, as the treat-
ment is not a pharma-
cological treatment, there
should be no serious ad-
verse physical outcomes
for these people.**
Transient elastography fibrosis stage F3 or worse
Cut-off around 9.5 kPa
(range 8.0 to 11.0). Se-
vere fibrosis.
Sensitivity 0.92 (95% CI
0.89 to 0.96)
Specificity 0.70 (95% CI
0.61 to 0.79)
LR+ 3.1 (95% CI 2.1 to
4.1)
LR- 0.11 (95% CI 0.06 to
0.16)
564 participants (8 stud-
ies)
61% (range 25% to 88%) With a prevalence of 61%,
610 out of 1000 people
will have severe fibrosis.
Of these 610 people, 49
(8% of 610) people will be
missed as having severe
fibrosis. A clinical follow-
up can provide physicians
with knowledge for the
next diagnostic step that
should be taken
The remaining 390 peo-
ple will not have severe
fibrosis. 117 people (30%
of 390), i.e., the false
positives, will have un-
necessary worries about
their liver fibrosis stage.
However, as the treat-
ment is not a pharma-
cological treatment, there





The overall quality of the
studies in terms of bias
risk was assessed as
moderate
2 (25%) of the studies in-
cluded 20 or <20 partici-
pants.
Study design (mixed aeti-
ologies); risk of selection
bias (not all participants

































































































































Transient elastography fibrosis stage F4
Cut-off of 12.5 (most
common). Cirrhosis.
Sensitivity 0.95 (95% CI
0.87 to 0.98)
Specificity 0.71 (95% CI
0.56 to 0.82)
LR+ 3.3 (95% CI 2.1 to
5.0)
LR- 0.07 (95% CI 0.03 to
0.19)
330 participants (7 stud-
ies)
51% (range 15% to 79%) With a prevalence of 51%,
510 out of 1000 peo-
ple will have cirrhosis. Of
these 510 people, 26 (5%
of 510) people will be
missed as having severe
fibrosis. A clinical follow-
up can provide physicians
with knowledge for the
next diagnostic step that
should be taken
The remaining 490 peo-
ple will not have cirrhosis.
143 (29% of 490) peo-
ple, i.e., the false posi-
tives, will have unneces-
sary worries about their
liver fibrosis stage. How-
ever, as the treatment
is not a pharmacological
treatment, there should be
no serious adverse phys-




The overall quality of the
studies in terms of bias
risk was assessed as
moderate
3 (43%) of the studies in-
cluded 20 or <20 partici-
pants.
Study design (mixed aeti-
ologies); risk of selection
bias (not all participants
included in the analyses)
LR+: likelihood ratio positive; LR-: likelihood ratio negative.
* The post-test probability when the test is positive and when the test is negative is calculated based on the pre-test probability estimated
by the prevalence of significant fibrosis.
** We considered the mean prevalence of significant or severe fibrosis for the calculations of the number reported in ’Consequences in
a cohort of 1000 participants’. The number of false negatives were calculated using the pooled summary sensitivity, and the number of
false positives were calculated using the summary specificity (as reported in the table).
Note: the results in this table should not be interpreted in isolation from the results of the individual included studies contributing to each

































































































































D I S C U S S I O N
Summary of main results
In this review, we aimed to determine the diagnostic accuracy
of transient elastography for the diagnosis of hepatic fibrosis in
people with alcoholic liver disease compared with the reference
standard, liver biopsy. We also attempted to identify the optimal
cut-off values for the five stages of hepatic fibrosis. We identified
21 studies including participants with alcoholic liver disease of
which only 14 studies with 834 participants provided data for the
review analyses and hence constituted the included studies of this
review. In addition to published article data, we used individual
participant data obtained through correspondence with authors of
seven of these studies. Participants in all 14 studies had undergone
both transient elastography and liver biopsy investigations. The
lack of usable data from seven out of 21 studies raised the risk of
outcome reporting bias.
Study authors used a variety of different cut-off values for transient
elastography in an attempt to discriminate between the stages of
hepatic fibrosis. Hence, our analyses using the most common cut-
off values did not allow us to establish the best cut-off values for
the separate stages of hepatic fibrosis that could be recommended
for clinical practice.
Detection of fibrosis F0 or F1 is of no clinical relevance as these
initial hepatic fibrosis stages do not influence prognosis and if
the person abstains from alcohol consumption, the fibrosis will
reverse.
Transient elastography for F2 or worse
For F2 or worse with a cut-off of around 7.5 kPa, summary sensi-
tivity was 0.94 and specificity was 0.89. Prevalence of F2 or worse
was 81%. Most of the participants were alcohol abusers.
Transient elastography for F3 or worse
For F3 or worse with a cut-off of around 9.5 kPa, summary sen-
sitivity was 0.92 and specificity was 0.70. The result suggests that
transient elastography may rule out the presence of severe fibrosis,
considering the prevalence of 61%.
Transient elastography for F4
For F4 with a cut-off of 12.5 kPa, summary sensitivity was 0.95
and specificity was 0.71. The result suggests that transient elas-
tography could be useful to rule out the presence of cirrhosis fol-
lowing the data results of LR- and considering the prevalence of
51%. As the post-test probability becomes 7%, further testingmay
not be needed to rule out cirrhosis. Thus, liver biopsy could be
avoided. This result was consistent with the results of the anal-
ysis considering all the studies with the different cut-off values
(Figure 13) and the sensitivity analysis on the studies with time
interval between liver biopsy and transient elastography less than
three months (Figure 14), as the point representing the summary
sensitivity and specificity (summary operating point) was close to
the two hierarchical SROC curves.
Out of 1000 participants, we would identify 510 with cirrhosis,
but we would miss 26 people with cirrhosis and 143 participants
would be wrongly diagnosed due to transient elastography error.
Strengths and weaknesses of the review
The aims of our review were to provide pooled estimates of accu-
racy of transient elastography and to find the best cut-off values
of transient elastography for the five stages of hepatic fibrosis in
people with alcoholic liver disease.
We judged only 29% of the studies at low risk of bias. Despite the
fact that all included studies were published after 2003, that is, the
STARD initiative was published (www.stard-statement.org), clin-
ically relevant information was missing. We could not investigate
whether grade of inflammation, lengths of liver biopsy sample,
portal tracts, grades of steatosis, severity of fibrosis, and body mass
index as sources of possible heterogeneity had an impact on our
results because the collected data were not sufficient for analyses.
The role of transient elastography for determining the cut-off val-
ues for differentiating the five stages of hepatic fibrosis (F0 to F4)
in people diagnosed with alcoholic liver disease has not been pre-
viously validated. Therefore, this is the first diagnostic test accu-
racy review with meta-analyses that attempted to determine the
diagnostic test accuracy thresholds for distinguishing the stages
of hepatic fibrosis, focusing only on people with alcoholic liver
disease and using rigorous Cochrane Collaboration methodology
(SRDTA Handbook). However, due to the very few number of
studies assessing mild fibrosis and the huge variation of cut-off
values in studies with participants with significant or severe hep-
atic fibrosis or cirrhosis, we could not establish the optimal cut-
off values that could serve as thresholds for mild, significant, or
severe fibrosis and cirrhosis.
Variation of cut-off values is the main source of heterogeneity in
diagnostic studies. In addition, when studies reported accuracy
estimates considering similar cut-off values, our analyses showed
that some heterogeneity was still present, most probably due to
differences in clinical characteristics of the participants (abstinent
or not), as suggested by the variability of prevalence among the
studies.
The observed heterogeneity for F4 seemed to affect mainly the
specificity of transient elastography.
The small number of included studies with data for stages F2 or
worse and F3 or worse, was one of the limitations of our system-
atic review, as we could not perform a comprehensive analysis to
study the influence of potential sources of heterogeneity. Further-
more, the small number of studies might have had an effect on the
reliability of the estimates obtained by the bivariate or HSROC
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model, especially when some sensitivity analyses were performed.
In addition, in some analyses there was no evidence of heterogene-
ity in sensitivity, which we believe may be the main reason for the
failure of convergence of the statistical model. However, we have
been able to obtain accuracy estimates by fitting a model with the
random effect for only specificity. Unfortunately, in some sensi-
tivity analyses, the reason of lack of convergence of the statistical
models was not identified and we were unable to provide a sum-
mary result. Hence, our findings for stages F2 or worse and F3 or
worse (analyses with no more than 10 studies) might be limited
by the small number of studies. As the CIs for the obtained esti-
mates of hepatic fibrosis stages were wide, caution is needed when
interpreting the results.
A strength of our review is that we managed to obtain individual
patient data of people with alcoholic liver disease through corre-
spondence with authors of seven studies. By doing this, we de-
creased the amount of missing information and we were able to
increase the number of the included studies. Contacting Echosens
® with a request for published and unpublished studies yielded a
list with published studies only, so we failed at identification of
any unpublished studies relevant to the review questions.
We cannot judge if lack of intention to diagnose in seven of the
studies that included participants with various liver disease aeti-
ology and the lack of information in another study would have
affected the sensitivities and specificities of the transient elastog-
raphy, as it was impossible to conduct such analyses.
Despite that liver biopsy is considered the reference standard, it
may also present problems with its accuracy and reproducibility,
whichmay reflect on the true estimates of the accuracy of transient
elastography.
We could find only one systematic review that also included an
economic evaluation assessing FibroScan® for the detection of
hepatic fibrosis in people with suspected alcohol-related liver dis-
ease (Stevenson 2012). However, the authors identified only six
studies to 2010 and the authors concluded that, as the number
of people with suspected alcoholic liver disease was small in all
the studies, the estimated sensitivities and specificities were not
robust.
Only five studies reported results based on a pre-defined cut-off
and it was the cut-off established for chronic hepatitis C. We
were unable to define the optimal cut-off values for the stages of
hepatic fibrosis in people with alcoholic liver disease, as the data
that we obtained were not sufficient to perform the planned review
analyses. In addition, the lack of pre-specified cut-off values in
most of the included studies might have led to overestimation of
the accuracy of transient elastography.
Clinicians and researchers alike will be helped by knowing the
sensitivities and specificities of the most common cut-off values
used for staging of hepatic fibrosis in people with alcoholic liver
disease.
As transient elastography in our studies was not used as a screening
or a triage test, we could not present any results in a population
with a low prevalence of F3 or worse (significant hepatic fibrosis
or cirrhosis) or for F4 (cirrhosis alone) in people with alcoholic
liver disease. For clarity, we provided two tables.
Table 3 presented post-test probabilities obtained in our review
from minimum, medium, and high pre-test probabilities when
LR- is 0.11 (obtained in our analyses for F3 or worse). A negative
test result will convert a pre-test probability of 25%, 61%, and
88% to a post-test probability of 4%, 15%, and 45%. Hence,
the use of transient elastography to diagnose people with hepatic
fibrosis stage 3 or worse seems reasonable and could avoid liver
biopsy testing when the pre-test probability is not high.
Table 4 presented post-test probabilities obtained in our review
from minimum, medium, and high pre-test probabilities for hep-
atic cirrhosis (F4) with most common cut-off of 12.5 kPa when
the LR- is 0.07. A negative test result will convert a pre-test prob-
ability of 15%, 51%, and 79% to a post-test probability of 1%,
7%, and 21%. Hence, the use of transient elastography to diag-
nose people with F4 seems reasonable and could avoid liver biopsy
testing when the pre-test probability is not high.
The results of our review confirm that transient elastography is
an accurate test for differentiating the different stages of hepatic
fibrosis, also in the subgroup of people with alcoholic liver disease.
The high prevalence of significant or severe fibrosis and cirrhosis
found in the included studies has some consequences on the clin-
ical usefulness of transient elastography, as such scenarios are not
often encountered in clinical practice.When the pre-test probabil-
ity of cirrhosis is too high, clinicians should reconsider testing with
transient elastography, as it is unlikely to add any further relevant
information to the clinical diagnosis of cirrhosis. The more likely
reason for the high prevalence is in the aetiology of the liver dis-
ease. People with alcoholic liver disease visit clinicians when they
are at a more advanced stage of hepatic fibrosis than people diag-
nosed with other aetiologies of liver diseases. An advanced stage of
hepatic fibrosis, severe or worse, is easily recognised by clinicians,
which may limit the clinical utility of transient elastography test
in people with alcoholic liver disease.
We assessed transient elastography in people who had liver index
test conducted before, close to, or after the conduct of the refer-
ence standard, liver biopsy. As any post-liver biopsy intrahepatic
bleedingmay have affected the results of a following transient elas-
tography, this sequence of tests may have affected our results.
Applicability of findings to the review question
The aims of our review were to provide pooled estimates of di-
agnostic accuracy performance of transient elastography with re-
gard to the five stages of hepatic fibrosis in people with alcoholic
liver disease and their differentiation by finding the optimal cut-
off values for each stage of hepatic fibrosis.
Despite the fact that we could not establish the best cut-off values
for differentiating the hepatic fibrosis stages, we judged that our
review findings raise small applicability concerns defined through
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judgement of the three QUADAS-2 applicability domains: par-
ticipant selection, index test, and reference standard.
The included participants were people with alcoholic liver disease,
from various settings, and having different stages of hepatic fibro-
sis. We found a large variance of prevalence of the different stages
of hepatic fibrosis across the studies, but we believe that this does
not affect the applicability of our findings.
Transient elastography investigationswere performed as prescribed
by the manufacturers and as usually performed and reported in
clinical practice.
Liver biopsy was performed following the clinical guideline for
liver biopsy investigation andmorphological resultswere estimated
by the most often used semi-quantitative morphological scores.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We identified a small number of studies with a few participants
each and were unable to include several studies, which raises the
risk of outcome reporting bias. With these caveats in mind, tran-
sient elastography may be used as a diagnostic method to rule out
liver cirrhosis (F4) in people with alcoholic liver disease when the
pre-test probability is 51% (range 15% to 79%). Transient elas-
tography may also help in ruling out severe fibrosis (F3 or worse).
The use of transient elastography for severe fibrosis and cirrhosis
may lead to a reduced need for liver biopsy. Liver biopsy investi-
gation still remains an option if the certainty to rule in or rule out
the stage of hepatic fibrosis or cirrhosis remains insufficient after a
clinical follow-up or any other non-invasive test considered useful
by the clinician.
The proposed cut-off values for the different stages of hepatic fi-
brosis may be used in clinical practice, but one should be very cau-
tious, as those reported in this review were only the most common
cut-off values used by the study authors. The best cut-off values
for hepatic fibrosis in people with alcoholic liver disease could not
be established yet.
Implications for research
In order to obtain precise and reliable accuracy results of transient
elastography, used for diagnosing hepatic fibrosis in people with
alcoholic liver disease, prospective studies of adequate sample size,
enrolling only participants with alcoholic liver disease, need to be
performed. Hepatic fibrosis should be diagnosed with both tran-
sient elastography and liver biopsy (the reference standard) and
in this sequence, and the optimal cut-off values of transient elas-
tography should be identified and validated for hepatic fibrosis
in people with alcoholic liver disease. The time interval between
transient elastography and liver biopsy investigations in people
without cirrhosis should not exceed three months, and assessment
of results should be properly blinded, as only studies with low risk
of bias, fulfilling the Standards for Reporting of Diagnostic Accu-
racy (The STARD statement) may answer the review questions.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anastasiou 2010
Study characteristics
Patient sampling Prospective cohort study. Consecutive participants.
Patient characteristics and set-
ting
Number of participants: 14 participants diagnosed with alcoholic liver disease. See personal com-
munication in ’Notes’. Otherwise, 76 participants with chronic liver disease underwent liver biopsy,
transient elastography, and FibroTest/ActiTest
Index tests Transient elastography.
Target condition and reference
standard(s)
Participants with alcoholic liver disease and liver biopsy.
Flow and timing The interval between the liver biopsy and the transient elastography measurement was on the same
day following Anastasiou 2010 and 3 days, following personal communication on 27 July 2011
Comparative
Notes Email sent to J Anastasiou and colleagues 20 July 2011. Reply received 27 July 2011.
The following data were received through personal communication with J Anastasiou:
“Dear Dr Pavlov,
Thank you for taking into consideration our article.Our alcoholic liver disease groupwas categorized
as follows: 14 patients with liver fibrosis stage (METAVIR) F:0/1/2/3/4 of 8/2/0/0/4 respectively.
(table 1). Taking into account the size of the ALD (alcoholic liver disease) subgroup, only an F
(fibrosis) above or equal of 2, analysis was feasible.
The results are as follows:
Optimal cut-off value: 7.15 kPa
Sensitivity: 0.75
Specificity: 0.80
Positive predictive value: 0.89
Negative predictive value: 0.6
AUROC: 0.83
Asymptomatic significance: 0.06
The interval between the liver biopsy and the transient elastography measurement was 3 days.




Item Authors’ judgement Risk of bias Applicability concerns
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Anastasiou 2010 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Patient sampling Retrospective cohort study.
Patient characteristics and set-
ting
Only participants followed by trained addictologists with definite information regarding alcohol
consumption were included. People were excluded if they presented other causes of chronic liver
disease
37 participants corresponded to the study criteria and were considered for analyses (7 women and
30 men). 8 participants had liver biopsy during follow-up
Index tests Transient elastography.
Target condition and reference
standard(s)
Participants with alcoholic liver disease and liver biopsy.
Flow and timing 2 biopsies within 4 weeks, and 6 biopsies within the median of follow-up 32.5 weeks (15 weeks to
85 weeks)
Comparative
Notes No letter sent to the study authors. Unclear when liver biopsy was performed in the 8 participants,
but 8 participants had liver biopsy during follow-up. Transient elastography was performed at an
interval of more than 1 week apart by a senior operator
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
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Bardou-Jacquet 2013 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes





Patient sampling Prospective cross-sectional cohort study.
Patient characteristics and set-
ting
From personal communication, we obtained the information that “out of 390 patients, 106 had
alcoholic liver disease...” “Liver steatosis evaluation on liver biopsy was not available in our study.”
Hospitalised.
Index tests Transient elastography.
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Boursier 2009 (Continued)
Target condition and reference
standard(s)
Participants with alcoholic liver disease and liver biopsy.
Flow and timing 1 week.
Comparative
Notes Email sent to Jerome Boursier and colleagues 26 February 2013. Replies received 19 February 2013
and 21 May 2013. Individual participant data, sent by the study author, were used for our review
analyses. The impression is that liver biopsy was performed first and then transient elastography
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes




45Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Boursier 2009 (Continued)
of the results of the index tests?
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Retrospective cohort study.
Patient characteristics and set-
ting
4 people with alcoholic liver disease were included in the analyses (see personal communication in
’Notes’.). In total, 266 participants underwent FibroScan® .
Index tests Transient elastography.
Target condition and reference
standard(s)
People with alcoholic liver disease and liver biopsy.
Flow and timing Participants who were included between 1 May 2008 and 31 July 2011
Comparative
Notes Email sent 1 March 2013. Reply received 15 April 2013. Individual participant data, sent by the
study author, were used for our review analyses
Unclear of the sequence, but reported “All patients who underwent liver biopsy and FibroScan®
between 1 May 2008 and 31 July 2011”.
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Carl 2012 (Continued)
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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de Ledinghen 2013
Study characteristics
Patient sampling Prospective cohort study.
Patient characteristics and set-
ting
In our review analysis, we could include 34 participants as we received individual data
Index tests Transient elastography.
Target condition and reference
standard(s)
Participants with alcoholic liver disease and liver biopsy.
Flow and timing Within 1 week.
Comparative
Notes Email request sent about additional data to Victor De-Ledinghen on 22 July 2011. Received an
Excel sheet with data on 25 July 2011
In summary, retrieved data from 51 people with liver biopsy and transient elastography. After
removing duplicate entries of participants, 34 participants remained
It is not clear which test/investigation was performed first
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
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de Ledinghen 2013 (Continued)
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Retrospective study using data from a consecutive cohort of participants; among the people with
chronic liver disease with different aetiologies, 20 had alcoholic liver disease
Patient characteristics and set-
ting
There were 20 participants with alcoholic liver disease. See personal communication in ’Notes’
Index tests Transient elastography.
Target condition and reference
standard(s)
Participants with alcoholic liver disease and liver biopsy.
Flow and timing 2 months.
Comparative
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Dolman 2013 (Continued)
Notes Email sent to Grace Dolman on 26 May 2013. Replies received 18 June 2013, 9 April 2013, and
22 October 2013. Received individual data of interest to our review protocol on 20 participants
“There were 20 patients in our study with alcoholic liver disease. This was defined as the presence of
steatohepatitis with or without fibrosis, with alcohol as the most likely aetiology (and parenchymal
chronic liver screen negative). All patients had transient elastography and biopsy
AST was not routinely available in our centre at the time of the study, but I have included ALT as
requested. BMI was missing from the notes when we reviewed them for the study for all (BMI in 2
categories a) < 25 b) ≥25 kg/m2) but one patient. Steatosis was divided into 2 categories a) < 5%
steatosis; b) ≥ 5% steatosis
We did not calculate sensitivity/specificity by aetiology in the study due to the small numbers in
the cohort
Grace Dolman”
Participants were included if they had a liver biopsy within 2 months of a validated transient
elastography measurement
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Dolman 2013 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Retrospective cohort study.
Patient characteristics and set-
ting
139 people with alcoholic liver disease.
Index tests Transient elastography.
Target condition and reference
standard(s)
Participants with alcoholic liver disease and liver biopsy.
Flow and timing Within 6 months.
Comparative
Notes No email sent. Liver biopsy was performed first and then within the 6 months, participants under-
went transient elastography testing (among other tests)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Fernandez 2012 (Continued)
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Janssens 2010
Study characteristics
Patient sampling Prospective cohort study.
Patient characteristics and set-
ting
“Two hundred fifty-five patients admitted between January 1, 2006 and February 29, 2008 to our
unit for alcohol detoxification and rehabilitation
Final analysis was performed on a total of 49 patients (34 men and 15 women). Median age was 53
years (range: 29 to 73 y) and median body mass index was 25 (range: 17 to 38)
Number of patients: 49.
Sex: male/female: 34 men/15 women.
Age (years): 53 (29 to 73).
BMI = 25 (17 to 38).
AST = 87IU/l (25 to 311).
ALT = 51IU/l (17 to 168).”
Index tests Transient elastography.
Target condition and reference
standard(s)
Participants with alcoholic liver disease and liver biopsy.
Flow and timing Liver biopsy performed after transient elastography investigation in 1 week
Comparative
Notes No mail sent. The impression was that transient elastography was performed before liver biopsy.
See also p. 581 of the primary publication
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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Janssens 2010 (Continued)
dard?




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Prospective cohort study.
Patient characteristics and set-
ting
45 people with alcoholic liver disease enrolled.
Fibrosis stage assessed using the Batts-Ludwig scoring system
Aimof studywas to determine the diagnostic accuracy of the FibroScan® in the detection of cirrhosis
in people with alcoholic liver disease
Clinical data for 29 people with cirrhosis
Sex: male/female: 24 men/5 women.
Age (years): 47.9 ± 7.8.
BMI = 23.1 ± 3.8.
AST = 114.9 IU/L ± 71.4.
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Kim 2009 (Continued)
ALT = 62.6 U/L ± 92.2.
Clinical data for 16 people without cirrhosis
Sex: male/female: 13 men/3 women.
Age (years): 44.9 ± 7.5.
BMI = 23.1 ± 4.0.
AST = 81.8 IU/L ± 63.1.
ALT = 69.1 U/L ± 48.4.
Index tests Transient elastography.
Target condition and reference
standard(s)
Participants with alcoholic liver disease and liver biopsy.
Flow and timing Liver biopsy and transient elastography performed with the interval of 11.2 ± 22 days (0 to about
92 days)
Comparative
Notes Mail sent 26 March 2013 and replies received on the same day. Unclear, but FibroScan® was
mentioned before liver biopsy testing.
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Kim 2009 (Continued)
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Retrospective, cohort study. Participants with different chronic liver diseases
Patient characteristics and set-
ting
16 people with alcoholic liver disease. 418 participants in total
Index tests Transient elastography.
Target condition and reference
standard(s)
Participants with alcoholic liver disease and liver biopsy.
Flow and timing 8 participants (50%) had transient elastography at < 2 months, and 8 participants (50%) had
transient elastography at > 1.9 years to 8.6 years
Comparative
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Lannerstedt 2013 (Continued)
Notes Emails sent 28 February 2013. Replies received 21 May 2013 and 23 May 2013. We received
individual participant data (relevant to our review information) for 16 people with alcoholic liver
disease. It seems that liver biopsy was performed before transient elastography (it was also a ret-
rospective study). However, the time interval was most likely not an issue in terms of haematoma
should liver biopsy have been performed before transient elastography
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
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Lannerstedt 2013 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Yes





Patient sampling Prospective cohort study.
Patient characteristics and set-
ting
Alcoholic participants. 48 people had alcohol-related cirrhosis. (Another 44 had hepatitis C virus-
related cirrhosis.)
Index tests Transient elastography.
“Liver stiffness measurement was performed using FibroScan® (Echosens) by two experienced
operators who were not aware of the haemodynamic results. Briefly, FibroScan® was performed as
previously described on the right lobe of the liver, in the intercostal space with the patient lying
in dorsal decubitus with the right arm in maximal abduction. Only procedures with 10 validated
acquisitions, interquartile range ≤ 30% of the median value and a success rate of at least 70% were
considered reliable. The median value of all validated acquisitions was considered as LSM and the
results were expressed in kilopascal (kPa).”
Target condition and reference
standard(s)
Participants with alcoholic liver disease and liver biopsy.
Flow and timing Transient elastography and liver biopsy were performed on the same day
Comparative
Notes No mail sent. Transient elastography and liver biopsy (transjugular route) were performed on the
same day, and it seems that transient elastography was performed first
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
58Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lemoine 2008 (Continued)
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Mueller 2010
Study characteristics
Patient sampling Prospective cohort study of 101 people with alcoholic liver disease
Patient characteristics and set-
ting
Validation cohort: in the second part of the study, the study authors included 101 (73 men and
28 women) people with histologically staged alcoholic liver disease. (In the first part of the study,
sequential analyses of liver stiffness was performed in 50 people presenting at a university medical
centre for alcohol detoxification.)
Index tests Transient elastography.
Target condition and reference
standard(s)
Participants with alcoholic liver disease and liver biopsy.
Flow and timing A mean observation interval of 5.3 days. Range 3 to 10 days.
Comparative
Notes No mail sent. Unclear. The FibroScan® examination (with M probe) was performed at the time of
liver biopsy, i.e., at the same time in 100 participants
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Mueller 2010 (Continued)
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Prospective blinded cohort study that included consecutive participants with suspected alcoholic
liver disease
Patient characteristics and set-
ting
Out of 174 participants fulfilling the study inclusion criteria, 147 participants remained to be
included
Index tests Transient elastography.
Target condition and reference
standard(s)
Participants with alcoholic liver disease and liver biopsy.
Flow and timing Transient elastography and liver biopsy on the same day.
Comparative
Notes No mail sent. Liver biopsy seems to have been performed first, followed by transient elastography
on the same day
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Nahon 2008 (Continued)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Nahon 2008 (Continued)
Did all patients receive the same
reference standard?
Yes





Patient sampling Prospective cohort study.
Patient characteristics and set-
ting
The number of participants included in the final analyses was 103. Otherwise, 160 participants met
the inclusion criteria.
Rehabilitation outpatients and inpatients with alcohol abuse, prospectively included from April
2005 to January 2007
Index tests Transient elastography.
Target condition and reference
standard(s)
Participants with alcoholic liver disease and liver biopsy.
Flow and timing Transient elastography and liver biopsy on the same day.
Comparative
Notes No mail sent. It seemed that liver biopsy (percutaneously) was performed before transient elastog-
raphy. Both on the same day
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




63Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nguyen-Khac 2008 (Continued)
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
AST: aspartate aminotransferase; BMI: body mass index; F: fibrosis; FT/AT = FibroTest (ActiTest); LSM: liver stiffness measurement;
TE (FS): transient elastography (FibroScan®).
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Angulo 2009b Review article (serum markers).
Baba 2011 No reference standard.
Bureau 2008 Aim was to assess the correlation between liver stiffness and hepatic venous pressure gradient and to
investigate the performance of transient elastography for the diagnosis of significant portal hypertension
in participants with liver diseases (however, the cause of liver abnormalities in 51 (34%) out of 150
participants was alcohol)
Crespo 2010 Preliminary abstract published in 2010 of a study published later by Crespo 2012.
Crespo 2012 Only 4 participants with alcoholic liver disease. This information was received through email on 13
March 2014
“....Please find attached the individual data of the patients included. There were only 15 patients with
alcoholic disease, and among them 11 had been transplanted (so no alcohol-related liver disease at all
was present at the moment of biopsy and TE [transient elastography]). So in the end, there were only
4 ”pure“ immunocompetent patients with alcohol-related chronic liver disease. I have anyway included
the data required of all patients just in case you decide to use them. I regret the low number of patients
with which we can contribute to the review, and I understand you may decide not to use them
Thanks.
Gonzalo Crespo”
Ebinuma 2011 Aim was to evaluate the clinical utility of transient elastography with acoustic radiation force impulse
and to compare the results with this method and those of the FibroScan® procedure.
Fraquelli 2007 No data for the 5 people with alcoholic liver disease.
Ganne-Carrié 2006 Data on 75 people with alcoholic liver disease were expected to be received fromCeline Fournier working
at Echosens. We understood that the data are the property of the firm. In addition, it is written in the
publication that there is participant overlap with another study by Ziol et al. published in Ziol 2005
that had included people with chronic hepatitis C. Reading the 3 publications under the main reference
of the included study by de Ledinghen 2013, its seemed that data on the 75 participants that we were
interested in were a consistent part of the Excel sheet with individual participant data obtained through
personal communication with de Ledinghen on 8 March 2013. As we cannot be completely sure, we
refer to the Ganne-Carrié publication twice, i.e., under included and excluded studies
Gómez-Dominguez 2006 No data for the 3 people with alcoholic liver disease.
Ingiliz 2009 Aim was to investigate the liver stiffness measurement applicability and variability with reference to 3
probe positions according to the region of liver biopsy
Kircheis 2012 Reference standard was transient elastography.
Klibansky 2012 Aim of the study was to determine whether transient elastography could identify people with chronic
liver disease at risk of clinical decompensation
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(Continued)
Krawczyk 2011 Aim was to investigate variant adiponutrin as genetic determinant of liver fibrosis
Marinho 2007 Participants were with concomitant liver diseases.
McCorry 2012 Participants were suspected of having a chronic liver disease; however, aetiology was not reported
Nudo 2008 During the time of liver biopsy or FibroScan® measurements, people with alcoholic liver disease were
abstinent
Rath 2011 Only 2 people with alcoholic liver disease, i.e., the number of participants with alcoholic liver disease
was too low and the data were not given separately
Roulot 2011 Data on people with alcoholic liver disease alone could not be obtained separately
Stål 2009 Only 2 people with alcoholic liver disease. Some information on these 2 people was received from P Stål
on 20 June 2013
Trabut 2012 Only 1 person (too lownumber) with alcoholic liver disease. The information belowwas received through
email on 26 May 2013
“ ...... We only had 1 patient with alcoholic liver disease. The majority of the subjects in our study had
chronic hepatitis C. There were individuals biopsied for elevated liver enzymes of unknown etiology, but
alcohol consumption was not significant in these individuals and the biopsy histology was not consistent
with alcoholic liver disease
The one subject was male and 44 years old. BMI 25.9, FibroScan®= 48 kPa, Biopsy showed grade 3 and
stage 4 on both left and right liver lobes. (2 biopsies per lobe)
The biopsy and FibroScan® were performed 21 days apart.
Unfortunately that is all the data I have.
Please do not hesitate to contact me if you have any further question
Thank-you,
Carmine Nudo, MD CM, FRCPC”
BMI: body mass index.
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D A T A
Presented below are all the data for all of the tests entered into the review.






1 Transient elastography for F1 or
worse
1 103
2 Transient elastography for F2 or
worse
8 342
3 Transient elastography for F3 or
worse
10 760
4 Transient elastography for F3
or worse with cut-off values
around 9.5
8 564
5 Transient elastography for F3 or
worse with a cut-off value equal
to 9.5
5 221
6 Transient elastography for F4 14 834
7 Transient elastography for F4
(most common cut-off value =
12.5)
7 330
Test 1. Transient elastography for F1 or worse.
Review: Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease
Test: 1 Transient elastography for F1 or worse
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Nguyen-Khac 2008 79 1 16 7 0.83 [ 0.74, 0.90 ] 0.88 [ 0.47, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. Transient elastography for F2 or worse.
Review: Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease
Test: 2 Transient elastography for F2 or worse
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Anastasiou 2010 3 2 1 8 0.75 [ 0.19, 0.99 ] 0.80 [ 0.44, 0.97 ]
Boursier 2009 94 1 5 6 0.95 [ 0.89, 0.98 ] 0.86 [ 0.42, 1.00 ]
Carl 2012 3 0 0 1 1.00 [ 0.29, 1.00 ] 1.00 [ 0.03, 1.00 ]
de Ledinghen 2013 32 0 1 1 0.97 [ 0.84, 1.00 ] 1.00 [ 0.03, 1.00 ]
Dolman 2013 7 2 1 10 0.88 [ 0.47, 1.00 ] 0.83 [ 0.52, 0.98 ]
Kim 2009 39 0 1 5 0.98 [ 0.87, 1.00 ] 1.00 [ 0.48, 1.00 ]
Lannerstedt 2013 14 0 0 2 1.00 [ 0.77, 1.00 ] 1.00 [ 0.16, 1.00 ]
Nguyen-Khac 2008 62 2 15 24 0.81 [ 0.70, 0.89 ] 0.92 [ 0.75, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. Transient elastography for F3 or worse.
Review: Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease
Test: 3 Transient elastography for F3 or worse
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Boursier 2009 77 7 12 10 0.87 [ 0.78, 0.93 ] 0.59 [ 0.33, 0.82 ]
de Ledinghen 2013 26 1 4 3 0.87 [ 0.69, 0.96 ] 0.75 [ 0.19, 0.99 ]
Dolman 2013 4 4 1 11 0.80 [ 0.28, 0.99 ] 0.73 [ 0.45, 0.92 ]
Fernandez 2012 67 21 7 44 0.91 [ 0.81, 0.96 ] 0.68 [ 0.55, 0.79 ]
Janssens 2010 23 4 9 13 0.72 [ 0.53, 0.86 ] 0.76 [ 0.50, 0.93 ]
Kim 2009 35 2 1 7 0.97 [ 0.85, 1.00 ] 0.78 [ 0.40, 0.97 ]
Lannerstedt 2013 13 1 0 2 1.00 [ 0.75, 1.00 ] 0.67 [ 0.09, 0.99 ]
Mueller 2010 41 14 4 42 0.91 [ 0.79, 0.98 ] 0.75 [ 0.62, 0.86 ]
Nahon 2008 96 4 14 33 0.87 [ 0.80, 0.93 ] 0.89 [ 0.75, 0.97 ]
Nguyen-Khac 2008 46 10 7 40 0.87 [ 0.75, 0.95 ] 0.80 [ 0.66, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 4. Transient elastography for F3 or worse with cut-off values around 9.5.
Review: Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease
Test: 4 Transient elastography for F3 or worse with cut-off values around 9.5
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Boursier 2009 77 7 12 10 0.87 [ 0.78, 0.93 ] 0.59 [ 0.33, 0.82 ]
de Ledinghen 2013 28 2 2 2 0.93 [ 0.78, 0.99 ] 0.50 [ 0.07, 0.93 ]
Dolman 2013 4 4 1 11 0.80 [ 0.28, 0.99 ] 0.73 [ 0.45, 0.92 ]
Fernandez 2012 67 21 7 44 0.91 [ 0.81, 0.96 ] 0.68 [ 0.55, 0.79 ]
Kim 2009 35 2 1 7 0.97 [ 0.85, 1.00 ] 0.78 [ 0.40, 0.97 ]
Lannerstedt 2013 13 1 0 2 1.00 [ 0.75, 1.00 ] 0.67 [ 0.09, 0.99 ]
Mueller 2010 41 14 4 42 0.91 [ 0.79, 0.98 ] 0.75 [ 0.62, 0.86 ]
Nguyen-Khac 2008 46 10 7 40 0.87 [ 0.75, 0.95 ] 0.80 [ 0.66, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 5. Transient elastography for F3 or worse with a cut-off value equal to 9.5.
Review: Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease
Test: 5 Transient elastography for F3 or worse with a cut-off value equal to 9.5
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Boursier 2009 77 7 12 10 0.87 [ 0.78, 0.93 ] 0.59 [ 0.33, 0.82 ]
de Ledinghen 2013 28 2 2 2 0.93 [ 0.78, 0.99 ] 0.50 [ 0.07, 0.93 ]
Dolman 2013 4 4 1 11 0.80 [ 0.28, 0.99 ] 0.73 [ 0.45, 0.92 ]
Kim 2009 35 2 1 7 0.97 [ 0.85, 1.00 ] 0.78 [ 0.40, 0.97 ]
Lannerstedt 2013 13 1 0 2 1.00 [ 0.75, 1.00 ] 0.67 [ 0.09, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. Transient elastography for F4.
Review: Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease
Test: 6 Transient elastography for F4
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Anastasiou 2010 3 2 1 8 0.75 [ 0.19, 0.99 ] 0.80 [ 0.44, 0.97 ]
Bardou-Jacquet 2013 5 2 0 1 1.00 [ 0.48, 1.00 ] 0.33 [ 0.01, 0.91 ]
Boursier 2009 62 10 7 27 0.90 [ 0.80, 0.96 ] 0.73 [ 0.56, 0.86 ]
Carl 2012 1 1 0 2 1.00 [ 0.03, 1.00 ] 0.67 [ 0.09, 0.99 ]
de Ledinghen 2013 25 2 2 5 0.93 [ 0.76, 0.99 ] 0.71 [ 0.29, 0.96 ]
Dolman 2013 3 1 0 16 1.00 [ 0.29, 1.00 ] 0.94 [ 0.71, 1.00 ]
Fernandez 2012 51 11 6 71 0.89 [ 0.78, 0.96 ] 0.87 [ 0.77, 0.93 ]
Janssens 2010 16 7 4 22 0.80 [ 0.56, 0.94 ] 0.76 [ 0.56, 0.90 ]
Kim 2009 29 8 0 8 1.00 [ 0.88, 1.00 ] 0.50 [ 0.25, 0.75 ]
Lannerstedt 2013 8 4 0 4 1.00 [ 0.63, 1.00 ] 0.50 [ 0.16, 0.84 ]
Lemoine 2008 36 1 4 7 0.90 [ 0.76, 0.97 ] 0.88 [ 0.47, 1.00 ]
Mueller 2010 25 15 1 60 0.96 [ 0.80, 1.00 ] 0.80 [ 0.69, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
(Continued . . . )
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Nahon 2008 66 12 13 56 0.84 [ 0.74, 0.91 ] 0.82 [ 0.71, 0.91 ]
Nguyen-Khac 2008 28 11 5 59 0.85 [ 0.68, 0.95 ] 0.84 [ 0.74, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 7. Transient elastography for F4 (most common cut-off value = 12.5).
Review: Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease
Test: 7 Transient elastography for F4 (most common cut-off value = 12.5)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bardou-Jacquet 2013 5 2 0 1 1.00 [ 0.48, 1.00 ] 0.33 [ 0.01, 0.91 ]
Boursier 2009 62 10 7 27 0.90 [ 0.80, 0.96 ] 0.73 [ 0.56, 0.86 ]
de Ledinghen 2013 25 2 2 5 0.93 [ 0.76, 0.99 ] 0.71 [ 0.29, 0.96 ]
Dolman 2013 3 1 0 16 1.00 [ 0.29, 1.00 ] 0.94 [ 0.71, 1.00 ]
Kim 2009 29 8 0 8 1.00 [ 0.88, 1.00 ] 0.50 [ 0.25, 0.75 ]
Lannerstedt 2013 8 4 0 4 1.00 [ 0.63, 1.00 ] 0.50 [ 0.16, 0.84 ]
Mueller 2010 25 15 1 60 0.96 [ 0.80, 1.00 ] 0.80 [ 0.69, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Semi-quantitative histopathological scoring systems for progression of fibrosis to cirrhosis. Conversion grid for the
stages of hepatic fibrosis*
Stage of estimated fibrosis
METAVIR Knodell Ishak Kleiner Desmet Brunt Batts-Ludwig
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Table 1. Semi-quantitative histopathological scoring systems for progression of fibrosis to cirrhosis. Conversion grid for the
stages of hepatic fibrosis* (Continued)
F0 F0 F0 F0 F0 F0 F0
F1 F1 F1 F1 F1 F1 F1
F1 F1 F2 F1 F1 F1 F1
F2 F3 F3 F2 F2 F2 F2
F3 F3 F4 F2 F3 F3 F3
F4 F4 F5 F3 F4 F4 F4
F4 F4 F6 F4 F4 F4 F4
F: stage of hepatic fibrosis
F0: no fibrosis; F1: portal fibrous expansion; F2: thin fibrous septa emanating from portal triads; F3: fibrous septa bridging portal triads
and central veins; F4: cirrhosis. Clinically significant fibrosis is generally defined as F2 or worse (on the METAVIR scale from F0 to F4
with F4 being cirrhosis).
METAVIR, Knodell, Ishak, Kleiner, Desmet, and Brunt scoring systems are used to classify fibrosis (and steatosis) due to alcoholic liver
disease. For references, please see review text.
*Adapted from Goodman 2007.
Table 2. Nonalcoholic Steatohepatitis Clinical Research Network scoring system for grade of hepatic steatosis
Evaluation of parenchymal involvement by steatosis Steatosis grade
< 5% 0
5% to 33% 1
34% to 66% 2
> 66% 3
Table 3. Post-test probabilities (calculated in case of negative test results), starting from three pre-test probabilities for F3 or
worse with a cut-off around 9.5 kPa
Pre-test probability LR- Post-test probability
25% (minimum)* 0.11 4%
61% (mean)* 0.11 15%
88% (maximum)* 0.11 45%
F3 or F4: significant hepatic fibrosis or cirrhosis (or both) in participants with alcoholic liver disease.
* as it is reported in this review.
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Table 4. Post-test probabilities (calculated in case of negative test results), starting from three pre-test probabilities for F4 with
most common cut-off of 12.5 kPa
Pre-test probability LR- Post-test probability
15% (minimum)* 0.07 1%
51% (mean)* 0.07 7%
79% (maximum)* 0.07 21%
F4: cirrhosis.
* as it is reported in this review.
A P P E N D I C E S
Appendix 1. Search strategy
Database date of search Search strategy
Cochrane Hepato-Biliary Group Con-
trolled Trials Register
August 2014 (transient elastograph* OR fibroscan) AND ((hepatic OR liver)
AND (fibrosis OR cirrhosis)) AND liver biops*
Cochrane Hepato-Biliary Group Diagnos-
tic Test Accuracy Register
August 2014 (transient elastograph* OR fibroscan) AND ((hepatic OR liver)
AND (fibrosis OR cirrhosis)) AND liver biops*
The Cochrane Library Issue 7 of 12, 2014 #1 MeSH descriptor: [Elasticity Imaging Techniques] explode
all trees
#2 transient elastograph* or fibroscan
#3 #1 or #2
#4 MeSH descriptor: [Liver Cirrhosis] explode all trees
#5 (hepatic or liver) and (fibrosis or cirrhosis)
#6 #4 or #5
#7 MeSH descriptor: [Biopsy, Needle] explode all trees
#8 liver biops*
#9 #7 or #8
#10 #3 and #6 and #9
MEDLINE (OvidSP) 1946 to August 2014 1. exp Elasticity Imaging Techniques/
2. (transient elastograph* or fibroscan).mp. [mp=title, abstract,
original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word,
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(Continued)
rare disease supplementary concept word, unique identifier]
3. 1 or 2
4. exp liver cirrhosis/
5. ((hepatic or liver) and (fibrosis or cirrhosis)).mp. [mp=title,
abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique identi-
fier]
6. 4 or 5
7. exp Biopsy, Needle/
8. liver biops*.mp. [mp=title, abstract, original title, name of
substance word, subject heading word, keyword heading word,
protocol supplementary concept word, rare disease supplemen-
tary concept word, unique identifier]
9. 7 or 8
10. 3 and 6 and 9
EMBASE (OvidSP) 1974 to August 2014 1. exp elastography/
2. (transient elastograph* or fibroscan).mp. [mp=title, abstract,
subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name,
keyword]
3. 1 or 2
4. exp liver cirrhosis/
5. ((hepatic or liver) and (fibrosis or cirrhosis)).mp. [mp=title,
abstract, subject headings, headingword, drug trade name, orig-
inal title, device manufacturer, drug manufacturer, device trade
name, keyword]
6. 4 or 5
7. exp liver biopsy/
8. liver biops*.mp. [mp=title, abstract, subject headings, head-
ing word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword]
9. 7 or 8
10. 3 and 6 and 9
Science Citation Index Expanded 1900 to August 2014 #4 #3 AND #2 AND #1
#3 TS=(liver biops*)
#2 TS=((hepatic or liver) and (fibrosis or cirrhosis))
#1 TS=(transient elastograph* or fibroscan)
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use of index test and
setting):
The studies that fulfilled
the inclusion criteria of
this review should have
included participants of
any sex and ethnic ori-
gin, above 16 years old,
and who were diagnosed
with alcoholic liver dis-
ease. The participants
could have been hospi-
talised or outpatients
The diagnosis of alco-
holic liver disease should
have been established in
the study participants
based on registered his-
tory of alcohol excessive
intake of sufficient du-
ration and quantity to-
gether with clinical ev-
idence of liver disease
expressed with physical
signs at examination and
followed by laboratory
evidence of liver disease.
To ascertain the diagno-
sis of alcoholic liver dis-
ease and study the pres-
ence or absence of liver
fibrosis or cirrhosis or
both in each of the study
participants, both tran-
sient elastography and
liver biopsy should have
been performed
Describe the index test




sis conducted either be-
fore or after liver biopsy
The recommended tech-
nical parameters of tran-
sient elastography inves-
tigation are at least 10
validated stiffness mea-
surements at the same
measurement point, an
interquartile range of no
more than 30%, and
the ratio of the num-
ber of successful mea-
surements to the total in-
vestigational number of
acquisitions should be




standard and how it
was conducted and in-
terpreted:
Liver biopsy is useful in
establishing the grade of
hepatic fibrosis in people




the liver biopsy samples








work scoring system is
used for grading steatosis
(Kleiner 2005) (Table 2)
.
Describe any people
who did not receive the
index test(s) or refer-
ence standard (or both)
or who were excluded
from the 2 x 2 table
(refer to flow diagram)
: describe the time in-
terval and any inter-
ventions between in-
dex test(s) and refer-
ence standard:
As fibrosis may develop
rapidly with time, we ex-





longer than 6months, an




Was a consecutive or
random sample of par-
Were the index test re-
sults interpreted with-
Is the reference stan-
dard likely to clas-
Was there an appropri-
ate interval between in-
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(Continued)
ticipants enrolled?
Yes: all consecutive par-
ticipants or random sam-
ple of people with diag-
nosed alcoholic liver dis-





cient data were reported
to permit a judgement
out knowledge of the





knowledge of the results
of the liver biopsy
No: transient elastogra-
phy results were inter-
preted with knowledge
of the results of the liver
biopsy
Unclear: insuffi-
cient data were reported
to permit a judgement
sify the target condi-
tion correctly?
Yes: if all participants had
undergone liver biopsy
and the morphological
results were correctly re-
ported
No: if all participants
had not undergone liver
biopsy or morphological
results were not correctly
reported
Unclear: insuffi-
cient data were reported
to permit a judgement
dex test(s) and refer-
ence standard?
Yes: the interval between
the transient elastogra-
phy and liver biopsy was
≤ 6 months
No: the interval between
the transient elastogra-
phy test and liver biopsy
was > 6 months
Unclear: insuffi-
cient data were reported
to permit a judgement








to permit a judgement
If a threshold was used,
was it pre-specified?
Yes: if the threshold for
a positive test was pre-
specified.
No: if the threshold for a
positive test was not pre-
specified
Unclear: insuffi-
cient data were reported




edge of the results of
the index test?
Yes: liver biopsy results
were interpreted without
knowledge of the results
of the transient elastog-
raphy test
No: liver biopsy results
were interpretedwith the
knowledge of the results
of the transient elastog-
raphy test
Unclear: insuffi-
cient data were reported
to permit a judgement
Did all participants re-
ceive the reference stan-
dard?
Yes: all participants un-
derwent the reference
standard, liver biopsy
No: not all participants
underwent liver biopsy.
Unclear: insuffi-
cient data were reported
to permit a judgement
Did the study avoid in-
appropriate
exclusions?
Yes: the study avoided
inappropriate exclusions
(i.e., difficult to diagnose
participants)
No: the study excluded
patients inappropriately.
Unclear: insuffi-
cient data were reported
to permit a judgement
Did all participants re-
ceive the same reference
standard?
Yes: all participants re-
ceived the same refer-
ence standard, i.e., liver
biopsy
No: not all participants
received the same refer-
ence standard, i.e., liver
biopsy
Unclear: insuffi-
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cient data were reported
to permit a judgement
Were all participants




the selection criteria (se-
lected participants) were
included in the analysis,
or data on all the se-
lected participants were
available so that a 2 x
2 table including all se-
lected participants could
be constructed
No: not all participants
meeting the selection cri-
teriawere included in the
analysis or the 2 x 2 table
could not be constructed
using data on all selected
participants
Unclear: insuffi-
cient data were reported
to permit a judgement
Risk of bias: high/low/
unclear
Could the selection of
participants have intro-
duced bias?
High risk of bias: yes, if
the selection of partici-
pants introduced bias
Low risk of bias: no,
if the selection of par-
ticipants not introduced
bias
Unclear risk of bias: in-
sufficient data on partic-
ipants selection were re-
ported to permit a judge-
ment on the risk of bias
Could the conduct or
interpretation of the
index test have intro-
duced bias?
High risk of bias: if the
answer to the signalling
questions on the conduct
or interpretation of the
index test was “no”
Low risk of bias: if the
answer to the signalling
questions on the conduct
or interpretation of the
index test was “yes”
Unclear risk of bias: if
the answers to the 2
signalling questions on
the conduct or interpre-
tation of the index test
was either “unclear” or
Could
the reference standard,
its conduct, or its in-
terpretation have intro-
duced bias?
High risk of bias: if the
answer to the signalling
questions on the refer-
ence standard, its con-
duct, or its interpreta-
tion was “no”
Low risk of bias: if the
answer to the signalling
questions on the refer-
ence standard, its con-
duct, or its interpreta-
tion was “yes”
Unclear risk of bias: if





High risk of bias: if the
answer to the signalling
questions on flow and
timing was “no”
Low risk of bias: if the
answer to the signalling
questions on flow and
timing was “yes”
Unclear risk of bias: if
the answers to the 4 sig-
nalling questions on flow
and timing was either
“unclear” or any combi-
nation of “unclear” with
“yes” or “no”
77Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
any combination of “un-
clear” with “yes” or “no”
the reference standard,
its conduct, or its inter-
pretation was either “un-
clear” or any combina-






that the included par-
ticipants did not match
the review question?
High concern: there was
high concern that the
included participants do
not match the review
question
Low concern: there was
low concern that the in-
cluded participants did
not match the review
question
Unclear concern: if it was
unclear.
Were there concerns
that the index test, its
conduct, or interpreta-
tion differed from the
review question?
High concern: there was
high concern that the
conduct or interpreta-
tion of the transient
elastography test differs
from the way it is likely
to be used in clinical
practice
Low concern: there was
low concern that the
conduct or interpreta-
tion of the transient
elastography test differed
from the way it is likely
to be used in clinical
practice
Unclear concern: if it was
unclear.
Were there concerns
that the target condi-
tion as defined by the
reference standard did
not match the review
question?
High concern: all partic-
ipants did not undergo
liver biopsy for grading
hepatic fibrosis
Low concern: all partic-
ipants underwent liver
biopsy for grading hep-
atic fibrosis
Unclear concern: if it was
unclear.
-
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• We added a second objective: “In addition, to identify the optimal cut-off values for differentiating the five stages of hepatic
fibrosis.”
• We excluded study design (diagnostic cohort study designs compared to case-control study designs) from investigation of
heterogeneity, as it is a QUADAS-2 item. In addition, in our review, all included studies were cohort studies.
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